NZ336836A - Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments - Google Patents

Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments

Info

Publication number
NZ336836A
NZ336836A NZ336836A NZ33683698A NZ336836A NZ 336836 A NZ336836 A NZ 336836A NZ 336836 A NZ336836 A NZ 336836A NZ 33683698 A NZ33683698 A NZ 33683698A NZ 336836 A NZ336836 A NZ 336836A
Authority
NZ
New Zealand
Prior art keywords
alkyl
aryl
heteroaryl
hydrogen
alkoxy
Prior art date
Application number
NZ336836A
Inventor
Louis S Chupak
Mark C Noe
Michael A Letavic
Kim Francis Mcclure
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NZ336836A publication Critical patent/NZ336836A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/281,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/301,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96Sulfur atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D279/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/101,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/121,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings

Description

<div class="application article clearfix" id="description"> <p class="printTableText" lang="en">WO 98/34918 <br><br> PCT/TB98/00064 <br><br> -1- <br><br> 5 <br><br> ARYLSULFOMYL HYDROXAMIC ACID DERIVATIVES Background of the Invention The present invention relates to aryisutfonyl hydroxamie acid derivatives which are inhibitors of matrix metalloproteinases or the production of tumor necrosis factor 10 ■ (TNF) and as such are useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scisritis and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used 15 in combination therapy with standard non-steroidal anti-inflammatory drugs (hereinafter NSAICCS) and analgesics for the treatment of arthritis, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and alkaloids, such as vincristine, in the treatment of cancer. <br><br> This invention also relates to a method of using such compounds in the 20 treatment of the above diseases in mammals, especially humans, and to pharmaceutical compositions useful therefor. <br><br> There are a number of enzymes which effect the breakdown of structural proteins and which are structurally related metalioproteases. Matrix-degrading metalloproteinases, such as gelatinase, stromeiysin and coliagenase, are involved in 25 tissue matrix degradation (e.g. collagen collapse} and have been implicated in many pathological conditions involving abnormal connective tissue and basement membrane matrix metabolism, such as arthritis (e.g. osteoarthritis and rheumatoid arthritis), tissue ulceration (e.g. corneal, epidermal and gastric ulceration), abnormal wound healing, periodontal disease, bone disease (e.g. Pagefs disease and osteoporosis), tumor 30 metastasis or invasion, as well as HIV-infection (J. Leuk. Biol.. §£ (2): 244-248,1992). <br><br> Tumor necrosis factor is recognized to be involved in many infectious and autoimmune diseases (W. Fiers, FEBS Letters. 1991. 285.199). Furthermore, it has been shown that TNF is the prime mediator of the inflammatory response seen in sepsis and septic shock (C.E. Spooner at al., Clinical Immunology and Immunopatholoav. 1992, 35 62S11). <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -3- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -2- <br><br> Summarv of the invention The present invention relates to a compound of the formula R5 p6 <br><br> R4 \ / R8 <br><br> R' <br><br> 1/ \ <br><br> %r &gt; <br><br> so; <br><br> H <br><br> Q <br><br> or the pharmaceutically acceptable salt thereof, wherein the broken line represents an optional double bond; <br><br> X is carbon, oxygen, sulfur, SO, S02 or nitrogen; <br><br> Y is carbon, oxygen, sulfur, SO, SQ, or nitrogen; <br><br> R\ R2, R3, R4 R5, R6, R7, R8 and R9 are selected from the group consisting of hydrogen, hydroxy, (CVCeJalkyI optionally substituted by one or two groups selected from (Ci-CeJalkylthio, (CVC^alkoxy, trifluoromethyl, halo, (C6-Cn0)aryl, (C2-CB)heteroaryl, (C6-C10)arylamino, (C6-C10)arylthio, (Ce-C10)aryloxy, (C2-C9)heteroarylamino, (C2-C9)heteroarylthio, (C2-C9)heteroaryloxy, (C6-C10)aryl(C6-C10)aryl, (C3-C8)cycloalkyl, hydroxy, piperazinyl, (CB-C^JaryKCi-CaJalkoxy, (C2-C9)heteroaryl(C1-C6)alkoxy, (C^CeJacylamino, (Cr C6)acylthio, (CVCeJacyloxy, (CVCeJalkylsulfinyl, (C6-C10)arylsulfinyl, (C^CeJalkylsulfonyl, (C6-C10)arylsulfonyl, amino, (CrC6)alkylamino or ((CrCeJalkyO^mino; (C2-C6)alkenyl, (C6-Cio)aryl(C2-C6)alkenyl, (C2-C9)heteroaryl(C2-C6)alkenyl, (C2-Ce)alkynyl, (C6-C10)aryl(C2-C6)alkynyl, (C2-C9)heteroaryl(C2-C6)alkynyl, (CVC^alkylamino, (Ct-C^alkylthio, (C,-C6)alkoxy, perfluoro(C1-C8)alkyl, (C6-C10)aryl, (C2-C9)heteroaryl, (C6-C10)arylamino, (C6-C10)arylthio, (C6-C10)aryloxy, (C2-C9)heteroarylamino, (C2-C9)heteroarylthio, (C2-C9)heteroaryloxy, (C3-C8)cycloalkyl, (CrCsJalkyKhydroxymethylene), piperidyl, (Cr C6)alkylpiperidyl, (CrCeJacylamino, (C^CeJacylthio, (CrCe)acfTtl«5U£5^0 a group of the formula <br><br> OF N.Z. <br><br> 1 4 jul 2000 <br><br> RCHFIVPn <br><br> 3J6836 <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> 10 <br><br> V <br><br> &lt;J&gt;y 11 <br><br> &lt;ch2)„ <br><br> » <br><br> wherein n is 0 to 6; <br><br> yisOorl; <br><br> W is oxygen or &gt;NR24; <br><br> Z is -OR11, -NR24R11, azetidinyi, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl or a bridged diazabicycloalky! ring selected from the group consisting of <br><br> 15 <br><br> 20 <br><br> ,&lt;ch2&gt; <br><br> &lt;ch2&gt; <br><br> m <br><br> (ch2) <br><br> •n' <br><br> I <br><br> V <br><br> (CHE)m cch2&gt;r <br><br> -H' <br><br> I <br><br> V <br><br> 25 <br><br> 30 <br><br> . (chj),. <br><br> SUBSTITUTE SHEET f'RULF 261 <br><br> INTELLECTUAL PROPERTY OFFICE OF N.Z. <br><br> 1 4 jul 2000 received <br><br> WO 98/34918 <br><br> wherein r is 1, 2 or 3; <br><br> mis1or2; <br><br> pis0or1;and <br><br> V is hydrogen, (Cf-CaJalkyl, (CrCgJalkyl^O)-, (C^Cg) alkoxy(OO)-, (Qr C10)aryl(G=O)-, (C6-C10)aryloxy(C=O)-, (Ce-C^aryKCrC^alkyKC^)-, (C6-C10)aryl-(C1-C6)alkoxy(C=0)-, or (CrC6)alkoxy(C=0)-0-; <br><br> wherein each heterocyclic group (i.e., each Z cyclic group containing one or more heteroatoms) may optionally be independently substituted by one or two groups selected from hydroxy, (Q-CeJalkyl, (CrC6)alkoxy, (CrC10)acyl, (C1-C10)acyloxy, (C6-C10)aryl, (Cz-C9)heteroaryl, (C8-C10)aryl(CrC6)alkyl, (CVAOheteroaryKCVCeJalkyl, hydroxy(C1-C6)alkyl, (Cr CeJalkoxy^rCeJalkyl, (CrCeJacyloxyfCVCeJalkyl, (CrC6)alkylthio, (CrC6)alkylthio(CrC6)alkyl, (C6-C10)arylthio, (C6-C10)arylthio(C1-C6)alkyl, R12R13N-, R12R13NS02-, R12R13N(C=0)-, R12R13N(C=0)-(C1-C6)alkyl, R14S02-, R14S02NH-, R15(C=0)-[N(R12)]-, R180(C=0)-, or R160(C=0)-(CrC6)alkyl; <br><br> wherein R10 is (^-CeJacylpiperazinyl, (C6-C10)arylpiperazinyl, (C2-C9)heteroarylpiperazinyl, (Q-CeJalkylpiperazinyl, (Ce-C^JaryKC^CeJalkylpiperazinyl, (C2-CgJheteroaryKCrCeJalkyipiperazinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidyl, (C,-C6)alkylpiperidyl, (C6-C10)arylpiperidyl, (C2-Ce)heteroarylpiperidyl, (C^CeJalkylpiperidyKC,-C6)alkyl, (C6-C10)arylpiperidyl(C1-C6)alkyl, (C2-C9)heteroaryl-piperidyl-(CrC6)alkyl or (Cr C6)acylpiperidyl; <br><br> R11 is hydrogen, (C6-C10)aryl, (C2-C9)heteroaryl, (Ce-C^JaryKCrCaJalkyl, (Cj,-C9)heteroaryl(C1-C6)alkyl, (C1-C6)alkyl(C6-C10)aryl(C1-C6)alkyl, (Ci-CgJalkyKCj-CgJheteroaryKC,-Cs)alkyl, 5-indanyl, -CHR170-(C=0)-R18 or -CH2(C=0)-NR19R20; <br><br> R12 and R13 are each independently hydrogen, (C,-C6)aikyl, (C6-C10)aryl, (C2-C9)heteroaryl, (C6-C10)aryl(C1-C6)alkyi or (Cj-CgJheteroaryKCVCeJalkyl or R12 and R13 may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or thiomorpholinyl ring; <br><br> R14 is trifluoromethyl, (C,-Ce)alkylf (QrC10)aryl, (C2-C9)heteroaryl, (Ca-C^JaryKC,-C6)alkyl or ((^-CgJheteroaryKCrC^alkyl; <br><br> R15 is hydrogen, (CVC^alkyl, (Q-C^alkoxy, (Ce-C10)aryl, (C2-C9)heteroaryl, (Cr CeJaryKC^CeJalkyKCa-C^JaryKCrCeJalkoxy or (Cj-C^JheteroaryKCrCeJalkyl; <br><br> R18 is (C^CeJalkyl, (Ce-C10)aryl, (Cj-CgJheteroaryl, (CVC^aryKCVCejalkyl, 5-indanyl, - <br><br> [CH(R17)]0-(C=0)-R18, -CH2(C=O)-NR19R20i or R^CKCrQJalkyl; lNltLLt(;TUAL PROPERTY OFFICE <br><br> OF N.Z. <br><br> 1 4 jul 2000 RFf!Cl\/cn <br><br> 536836 <br><br> WO 98/34918 PCT/IB98/00064 <br><br> -5- <br><br> R17 is hydrogen or (CrC^alkyl; <br><br> R18 is (C^CeJalkyl, (CVC^alkoxy or (C6-C10)aryl; <br><br> R18 and R20 are each independently hydrogen or (C,-Ce)alkyl or may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or thiomopholinyl ring; <br><br> R21 is H2N(CMR22)(C=OK <br><br> R22 is the side chain of a natural D- or L-amino acid; <br><br> R23 is hydrogen, (C,-C6)acylf (CVQalkyl, (Ce-CJaryKCrQOalkyl, ((VOOheteroaryKCr C6)alkyl or (C^-C^alkylsulfonyl; <br><br> R24 wherever it occurs is independently hydrogen or (C,-C8)alkyl; <br><br> or R1 and R2, or R3 and R4, or R5 and R6 may be taken together to form a carbonyl; <br><br> or R1 and R2, or R3 and R4, or R5 and R8, or R7 and R8 may be taken together to form a (C3-C6)cycloalkyl, oxacyclohexyl, thiocyclohexyl, indanyl or tetralinyl ring or a group of the formula <br><br> Q is (C-(-Cto)alkyl, (Cg-C^oJaryl, (Cg-C1o)aryloxy(C6-Cio)aryl, (Cg-C^o)aryl(Cg-Cio)aryl, (Cg-C10)aryl(C6-C10)aryl(CrC6)alkyl, (C6-C10)aryl(C1-C6)alkoxy(C1-C8)alkyl, (C6-C10)aryloxy(C2-C9)heteroaryl, (Cj-Cg)heteroaryl, (Ci-C8)alkyI(C8-Cig)aryl, (Ct-C8)alkoxy(Ca-Cfo)aryl, (C8-CioJaryKCrCsJalkoxy^a-CujJaryl, (C2-C0)heteroaryloxy(C6-C1o)aryl, (C^CeJalkyKCj-C9)heteroaryl, (C1-C6)alkoxy(C2-C9)heteroaryl, (C1-C9)heteroaryl(C1-C8)alkoxy(C6-C10)aryl, (C2-Ca)heteroaryloxy(C2-C9)heteroaryl, (C8-C10)aryloxy(C1-C8)alkyl, (C2-C9)heteroaryloxy(C1-C6)alkyl, (C1-C8)alkyl(C8-C10)aryloxy(C6-C10)aryl, (CrC6)alkyl(C2-C9)heteroaryloxy(C8-C10)aryl, (Ci-C6)alkyl(C8-C10)aryloxy(C2-C9)heteroaryl, (CrCeJalkoxyCCB-C^JaryloxyfCVCmJaryl, (Cr C6)alkoxy(C2-C9)heteroaryloxy(C6-C10)|ryl or (C1-C6)alkoxy(C8-C10)aryloxy(C2-C9)heteroaryl optionally substituted by fluoro, chloro, (C,-C6)alkyl, (CrCeJalkoxy or perfluoro(C1-C3)alkyl; <br><br> with the proviso that when y is zero, Q is other than (Q-C10)aryl(C8-C10)aryl, (C,,-CmJaryKCrCaJalkoxy^B-C^Jaryl or (C1-C9)heteroaryl(C1-C6)alkoxy(C,-C10)aryl, and anyone of R1-R9 is a group of formula II then 2 must be substituted when defined as azetidinyl, <br><br> pyrrolidinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindoliny tetrahydroquinolinyl. <br><br> INTELLECTUAL PROPERTY OFFICE OF N.2 <br><br> 1 jul 2000 <br><br> Dtrrciucn <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> tetrahydroisoquinolinyl, piperazinyl, (CVC^acylpiperazinyl, (C^C^alkylpiperazinyl, (CV C10)arylpiperazinyl, (C2-C9)heteroarylpiperazinyl or a bridged diazabicycloalkyl ring; <br><br> with the proviso that when y is zero, Q is other than (Q-C10)aryl(C6-C10)aryl, (0,-C10)aryl(C1-C6)alkoxy(C6-C10)aryl or (^-CsJheteroaryKC^-CgJalkoxyfCVC^aryl, then at least one of R1, R2, R3, R4, R5, R6, R7, R8 and R9 must be defined as the group of formula II; <br><br> with the proviso that when Q is (Q-CwJaryKCe-CwJaryl, (Ce-C^aryKC^C^alkoxyCCV C10)aryl or (C1-C9)heteroaryl(C1-C6)alkoxy(Ce-C10)aryl, then R1-R9 may be other than formula II but when R\ R2, R3, R4, R5, R6, R7, R8, and R9 are all defined by hydrogen or (Q-CeJalkyl, either X or Y is oxygen, sulfur, SO, -SQ- or nitrogen, or the broken line represents a double bond; with the proviso that R7 is other than hydrogen only when R? is other than hydrogen; <br><br> with the proviso that R? is other than hydrogen only when R? is other than hydrogen; <br><br> with the proviso that R3 is other than hydrogen only when R4 is other than hydrogen; <br><br> with the proviso that R2 is other than hydrogen only when R1 is other than hydrogen; <br><br> with the proviso that when R\ R2 and R9 are a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 2- or 6- positions of the ring; <br><br> with the proviso that when X is nitrogen, R1 is not present; <br><br> with the proviso that when X is oxygen, sulfur, SO, SQ or nitrogen and when one or more of the group consisting of R1, R2, R5 and R8, is a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 4- or 6- positions; <br><br> with the proviso that when Y is oxygen, sulfur, SO, SQ or nitrogen and when one or more of the group consisting of R?, R4, R7 and R8, are independently a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 3- or 5- positions; <br><br> with the proviso that when X is oxygen, sulfur, SO or SQ, R3 and R4 are not present; <br><br> with the proviso that when y is 1 and W is NF?4 or oxygen, Z cannot be hydroxy; <br><br> with the proviso that when Y is oxygen, sulfur, SO or SQ, R5 and R6 are not present; <br><br> with the proviso that when Y is nitrogen, R3 is not present; <br><br> with the proviso that when the broken line represents a double bond, Ft and R6 are not present; <br><br> with the proviso that when R3 and R5 are independently a substituent comprising a heteroatom when the broken line represents a double bond, the heteroatom cannot be directly bonded to positions X and Y; <br><br> with the proviso that when either the X or Y position is oxygen, sulfur, SO, SQ&gt; or nitrogen, the other of X or Y is carbon; <br><br> INTELLECTUAL PROPERTY OFFICE OF N.Z. <br><br> 1 4 JUL 2000 <br><br> u o <br><br> WO 98/34918 <br><br> PCT/TB98/00064 <br><br> -7- <br><br> with the proviso that when X or Y is defined by a heteroatom, the broken line does not represent a double bond. <br><br> The term "alky!*, as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched or cyclic moieties or 5 combinations thereof. <br><br> The term "alkoxy*, as used herein, indudes O-aikyl groups wherein 'alkyl* is defined above. <br><br> The term 'aryl', as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as 10 phenyl or naphthyi, optionally substituted by 1 to 3 substituents independently selected from the group consisting of fluoro, chloro, cyano, nitro, trifluoromethyl, (C,-C9)alkoxy, (Ce-C,0)aryioxy, trifluoromethoxy, difluoromethoxy and (C,-C8)aikyt. <br><br> The term 'heteroaryf*, as used herein, unless otherwise indicated, inciudes an organic radical derived from an aromatic heterocyclic compound by removal of one 15 hydrogen, such as pyridyi, furyl, pyroyi, thienyi, isothiazolyl, imidazolyl, benzimidazolyl, tetrazolyl, pyrazinyt, pyrimidyl, quinolyl, isoquinolyl, benzofuryl, isobenzofuryl, benzothienyl, pyrazolyl, indolyl, isoindolyt, purinyl, carbazolyl, isoxazolyl, thiazolyl, oxazolyl, benzthiazoiyl or benzoxazolyl, optionally substituted by 1 to 2 substituents independently selected from the group consisting of fluoro, chloro, trifluoromethyl, (Cr 20 Cs)alkoxy, (Ca-C10)aryioxy, trifluoromethoxy, difluoromethoxy and (C,-C„)alkyl. <br><br> The term 'acyl', as used herein, unless otherwise indicated, includes a radical of the general formula RCO wherein R is alkyl, alkoxy (such as methyioxy carbonyl), aryl. arylalkyl or arylalkyloxy and the terms 'alkyl* or "aryl* are as defined above. <br><br> The term 'acyioxy*, as used herein, inciudes O-acyl groups wherein 'acyl' is 25 defined above. <br><br> The term 'D- or L-amino acid', as used herein, unless otherwise indicated, includes glycine, alanine, valine, leucine, isoleucine, phenylalanine, asparagine, glutamine, tryptophan, proline, serine, threonine, tyrosine, hydroxyproiine, cysteine, cystine, methionine, aspartic add, glutamic add, lysine, arginine or histidine. 30 The positions on the ring of formula I, as used herein, are defined as follows: <br><br> INTELLECTUAL PROPERTY OFFICE OF N.Z. <br><br> i * jul 2000 RECEIVED <br><br> WO 98/34918 <br><br> PCT/DB98/00064 <br><br> -8- <br><br> 5 N <br><br> 4 <br><br> Y. <br><br> 3 <br><br> 2 <br><br> N' 1 <br><br> The preferred conformation of the compound of formula I inciudes hydroxamic acid axially disposed in the 2-position. <br><br> The compound of formula I may have chiral centers and therefore exist in different enantiomeric forms. This invention relates to all optical isomers and stereoisomers of the compounds of formula I and mixtures thereof. <br><br> Preferred compounds of formula I include those wherein Y is carbon. <br><br> Other preferred compounds of formula I include those wherein Q Is (C,-C9)alkoxy(C9-C,0)aryl. (C8-Cie)aryl(C,-C8)alkoxy(C8-C10)aryl, or (C8-C10)aryt(C,-C„)alkoxy(C, -C8)aikyl wherein each terminal aryl group is optionally substituted by fluoro. <br><br> Other preferred compounds of formula I include those wherein RJ, R\ Ra, R7 and R* are hydrogen. <br><br> More preferred compounds of formula I include those wherein Y is carbon; Q is (C, -CB)alkoxy(C9-C, 0)aryl, (C9-C, 0)aryl(C, -C8)alkoxy(C8-C, 0)aryl, or (C9-C10)aryl(C,-C8)alkoxy(C,-C8)alkyl. <br><br> Specific preferred compounds of formula I include the following: <br><br> {2E.4B)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxyiic acid; <br><br> (2B,4S)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid methyl ester; <br><br> (2B,4B)-1-[3-(4-Fluorophenoxy)-propane-1-suifonyl]-2-hydroxycarbamoyl-piperidine-4-carboxyiic acid; <br><br> (2Rl4B)-1-[3-(4-Fluorophenoxy)-propane-1-sulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic acid methyl ester; <br><br> (2Q,3§)-{1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidin-3-yi}-carbamic acid isopropyl ester; <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -10- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -9- <br><br> 3-{S)-4-(4,-Fluorobiphenyl-4-sutfonyl)-2,2-dimothyl-thiomorpholine-3-carboxylic acid hydroxyamide; <br><br> 3-(§)-4-[4-{4-Fluorobenzyloxy)benzenesuifonyl]-2,2-dimethyl-thiomorpholine-3-carboxytic acid hydroxyamide; <br><br> (2B.4§)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-4-hydroxy-piperidine-2-carboxytic acid hydroxyamide; and <br><br> (2R,4B)*1 -(4-Methoxybenzenesulfonyl)-4-(piperazine-1 -carbony1)-piperidine-2-carboxylic add hydroxyamide hydrochloride. <br><br> Other compounds of the invention include: <br><br> (3S)-4-[4-(2-Chloro-thiazol-5-ylmetboxy)-benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3-carboxyiic acid hydroxyamide; <br><br> (3S)-2,2-Dimethyl-4-[4-(thiazol-5-ylmethoxy)-benzenesuJfonyi]-thiomorpholine-3-carboxylic add hydroxyamide; <br><br> (3S)-2,2-Dimethyt-4-[4-{pyridin-4-yfmethoxy)-benz0nesuffonyl]«thlomorpholine-3-carboxylic add hydroxyamide; <br><br> (3£)-4-{4-[2-{4-Fluorophenyl)-ethoxy]-benzenesulfonyl}-2,2-dimethyl-thlomorpholine-3-carboxylic add hydroxyamide; <br><br> (3§)-2,2-Dimethyl-4-{4-{2-pyridin-4-yl-ethoxy)-benzenesutfonyll-thiomorpholine-3-carboxylic add hydroxyamide; <br><br> (3S)-4-[4-(BenzothiazoU2-yimethoxy)-benzenesulfonyl]-2,2-dimethyl-thiomorphoiine-3-carboxyiic add hydroxyamide; <br><br> (3§)-2,2-Dimethyl-4-[4-(5-trifluoromethyl-benzothiazol-2-ylmethoxy)-benzenesutfonyl]-thiomorphoHne-3-carboxylic acid hydroxyamide; <br><br> (3S)-2,2-Dimethyi-4-[4-(1H-tetrazol-6-yimethoxy)-benzenesutfonyl]-thiomorphoKne-3-carboxylic add hydroxyamide; <br><br> (2B,3S)-{1-[4-(2-Chloro-thiazol-5-ylmethoxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidin-3-yt}-carbamic add methyl ester; <br><br> (2B,3§)-{2-Hydroxycarbamoyl-1-[4-(thiazol-5-ylmethoxy)-benzenesulfonyl]-piperidin-3-yl}-carbamic add methyl ester; <br><br> (2B,3S)-{2-Hydroxycarbamoyl-1-[4-(pyridin-4-ylmethoxy)-benzenesulfonyl]-piperidin-3-yl}-carbamic add methyl ester; <br><br> (2B,3§)-{1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidin-3-yl&gt;-carbamic add methyl ester; <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -11- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -10- <br><br> (2R, 3S)-( 1 -{4- [2-(4-Ruorophenyl)-«thoxy]-bonzenesutfonyl} -2-hydroxycarbamoyt-piperidin-3-yt)-carbamic acid methyl aster; <br><br> (2B,3S)*{2-Hydroxycarbamoyl-1-[4-(2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-piperidin-3-yl}-carbamic acid methyl ester; <br><br> 5 (2R.3SH 1 -[4-{Benzothlazol-2-ylmethoxy)-benzenesulfonyl]-2-hydroxycarbamoyl- <br><br> piperidin-3-yl&gt;-carbamic acid methyl ester; <br><br> (2R,3£H2-Hydroxycarbamoyl-1-[4-{5-Wfluoromothyi-bertzothiazol-2-ylmethoxy)-benzer&gt;esutfonyl}-piperidin-3-yl}-carbamic acid methyl ester; <br><br> (2B,3S)-{2-Hydroxycarbamoyl-1-[4-{1hi-tetrazol-5-ylmethoxy)-benzenesijtfonyl]-10 piperidin-3-yl}-carbamic acid methyl ester; <br><br> (2fl,3§)-1-[4-(2-Chloro-thlazol-6-ylmethoxy)-benzenesuifonyl]-3-hydroxy-piperidine-2-carboxylic acid hydroxyamide; <br><br> (2R,3§)-3-Hydroxy-1-[4-(thiazol-5-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide; 15 (2B,3S)-3-Hydroxy-1-[4-(pyridin-4-ylmethoxy)-benzenesulfonyl]-piperidlne-2- <br><br> carboxylic add hydroxyamide; <br><br> (2Bi3§)-1-[4-(4-Ruorobenzyloxy)-benzenesulfonyl)-3-hydroxy-piperidine-2-carboxylic add hydroxyamide; <br><br> (2R,3S}-1-{4-[2-(4-Ruorophenyl)-ethoxy]-benzenesulfonyl}-3-hydroxy-piperidine-20 2-carboxyiic add hydroxyamide; <br><br> (2B,3S)-3-Hydroxy-1-l4-(2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-piperidine-2-carboxylic add hydroxyamide; <br><br> (2B,3S}-1-[4-(Benzothiazol-2-ylmethoxy)-benzenesulfonyi]-3-hydroxy-piperidine-2-carboxyiic add hydroxyamide; <br><br> 25 (2Bi3§)-3-Hydroxy-1-[4-(5-trifluoromethyl-benzothiazol-2-ylmethoxy)- <br><br> benzenesuHonyi]-piperidine-2-carboxylic acid hydroxyamide; <br><br> (2fi,3§)-3-Hydroxy-1 -[4-{1 H-tetrazol-5-ylmethoxy)-benzenesulfonyl]-piperidine-2-carboxylic add hydroxyamide; <br><br> (2fl,3§)-1 -[4-{2-Chloro-ttiiazol-5-ytmethoxy)-benzenesuHbnyl]-3-hydroxy-3-methyl-30 piperidine-2-carboxylic acid hydroxyamide; <br><br> (2B,3§)-3-Hydroxy-3-methyl-1-[4-(thiazol-5-ylmethoxy)-benzenesulfonyl]-piperid'me-2-carboxytic add hydroxyamide; <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -12- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -11- <br><br> (2B.3§)-3-Hydroxy-3-methyl-1-[4-(pyridin-4-ylmethoxy)-benzenesuifonyl]-piperidine-2-carboxytic acid hydroxyamide; <br><br> (2B.3S)-1 -[4-(4-Ruorobenzyioxy)-benzenesu)fonyi]-3-hydroxy-3^ri0thyl-pipefjdin8- <br><br> 2-carboxyiic add hydroxyamide; (2Q,3§)-1-{4-[2-(4-Fluorophenyl)-ethoxy]-benzenesuifonyl}-3-hydroxy-3-methyl- <br><br> piperidine-2-carboxylic acid hydroxyamide; <br><br> (2RJ3S)-3-Hydroxy-3-methyl-1-[4-{2-pyridin-4-yl-ethoxy)-benzenesuHonyl]-piperidine-2-carboxyiic add hydroxyamide; <br><br> (2fi,3§)-1 -[4-(B®nzothiazol-2-yimethoxy)-benzenesulfonyl]-3-hydroxy-3-methyl-piperidine-2-carboxylic add hydroxyamide; <br><br> (2B.3S)-3-Hydroxy-3-methyl-1-[4-{5-trifluoromethyi-benzothiazol-2-yimethoxy)-benzenesuifonyf]-piperidine-2-carboxyiic acid hydroxyamide; <br><br> (2B.31)-3-Hydroxy-3-methyH -[4-(1 H-tetrazol-5-ytmethoxy)-benzenesulfonyl]-piperidine-2-carboxyiic add hydroxyamide; <br><br> (3R)-4-[4-(2-Chioro-thiazol-5-ylmethoxy)-benzenesulfonyl]-2,2-dimethyl-morpholine-3-carboxylic add hydroxyamide; <br><br> (3R)-2,2-Dimethyl-4-[4-(thiazol-5-ylmethoxy)-benzenesulfonyl]-morpholine-3-carboxyiic add hydroxyamide; <br><br> (3B)-2,2-Dimethyl-4-[4-{pyridin-4«ylmethoxy)-benzenesulfonyl]-morpholine-3-carboxylic add hydroxyamide; <br><br> (3B)-4-[4-(4-Fluorobenzyioxy)-benzenesuifonyll-2,2-dimethyl-morpholine-3-carboxyiic acid hydroxyamide; <br><br> (3R)-4-{4-[2-(4-F1uorophenyl)-ethoxy]-benzenesuifonyl}-2,2-dimethyl-morpholine- <br><br> 3-carboxyiic add hydroxyamide; (3R)-2,2-Dimethyl-4-[4-(2-pyridln-4-yl-ethoxy)-benzenesulfonyl]-morpholine-3- <br><br> carboxyiic add hydroxyamide; <br><br> (3B)-4-[4-(Benzothiazol-2-yimethoxy}-b6nzenesutfony)3-2,2-dimethy}-morpholin6-3-carboxyiic add hydroxyamide; <br><br> (3B)-2,2-Dimethyl-4-[4-(5-trifluoromethyi-ber»zothiazol-2-ylmethoxy)-benzenesutfonyl3-morpholine-3-carboxyiic add hydroxyamide; <br><br> (3B}-22-DimethyM-[4-{1H-tetrazol-5-ylmethoxy)-benzenesulfonyl]-morphoiine-3-carboxyiic add hydroxyamide; <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -13- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -12- <br><br> (2E&gt;4BJ-1-[4-(2-Chloro-thiazol-5-ylmethoxy)-benzenesulfonyil-2-hydroxycarb&amp;moyl-piperidin»4-cart&gt;oxyiic acid; <br><br> (2B,4S)-2-Hydroxyearbamoyl-1-[4-(thlazol-5-ylmathoxy)-benzone8u!fonylJ-piperidin®-4-carboxylic add; <br><br> (2R,4R)-2-Hydroxycarbamoyl-1-[4-(pyridin-4-ylmethoxy)-benzenesulfonyl]-piperidine-4-carboxylic add; <br><br> (2Q,4^-1-{4-{2-(4-FkJorophenyi)-«ithoxy]-b0nzenesuifonyi}-2-hydroxycarbainoyl-piperidine-4-carboxy)io add; <br><br> (2R,4R)-2-Hydroxycarbamoyl-1-[4-(2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-piperidine-4-carboxytic add; <br><br> (2R,4R}-1-[4-{Benzothiazol-2-yimethoxy)-benzenesLiffonyl]-2-hydroxycarbamoyl-piperidine-4-carboxylic add; <br><br> (2{3,4R)-2-Hydroxycarbamoyl-1-[4-{5-trifluoromethyi-benzothiazol-2-ylmethoxy)-benzenesulfonyi]-piperidine-4-carboxylic add; <br><br> (2B,4B)-2-Hydroxycarbamoyl-1-[4-(1H-tetrazol-B-ylmethoxy)-benzene8uJfonyl]-piperidine-4-carboxylic acid; <br><br> (3f^-4-[4-{2-Chloro-thiazol-5-ytmethoxy)-benzanesulfonyl]-3-methyl-morphofine-3-carboxyiic add hydroxyamide; <br><br> (3B)-3-M«thyl-4-[4-^hiazol-5-ylmethoxy)-benzariesuifonyf]-morpholine-3-cart&gt;oxyilc add hydroxyamide; <br><br> (3R)-^MathyM-[4-(pyridirv4-ytmerthoxy)-benzenesulfony1]-morpholin&amp;-3-carboxylic add hydroxyamide; <br><br> (3R)-4-[4-(4-Ruoroberizyloxy)-b»nzen«sulfony1]-3-m0thyi-morpholine-3-carboxyiic acid hydroxyamide; <br><br> (3@H-{4-[2-(4-Ruorophenyi)-ethoxy]-benzenesuffonyl}-3-methyi-morphoiine-3-carboxyiic add hydroxyamide; <br><br> (3R)-3-Methyl-4-[4-{2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-morpholine-3-carboxyiic add hydroxyamide; <br><br> (3R)-4-[4-{Benzothiazol-2-yimethoxy)-benzenesulfonyl]-3-methyt-morpholine-3-carboxylic add hydroxyamide; <br><br> (3Q)-3-M«thyl-4-[4-{5-trifluoromethyl-benzothiazol-2-yfrnethoxy)-benzenesutfony)]-morphofine-3-carboxyiic acid hydroxyamide; <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -14- <br><br> WO 98/34918 <br><br> PCT/1B98/00064 <br><br> -13- <br><br> (30)-3-Methyl-4-[4-{1H-tetrazol-5-ylmethoxy)-benzenesuifonyl]-morpholine-3-carboxyiic acid hydroxyamide; <br><br> (2B)-1*[4-(2-Chloro-thiazol-5-ylmethoxy)-benzenesulfonyl]-2-methyI-3-oxo-piperidine-2-carboxyiic acid hydroxyamide; <br><br> 5 (2B)-2-Methyt-3-oxo-1 -[4-(thiazol-6-ylmethoxy)-benzenesulfonyl]-piperidine-2- <br><br> carboxyiic add hydroxyamide; <br><br> (2B)-2-Methyl-3-oxo-1-[4-(pyridin-4-ylmethoxy)-ber»zenesulfonyl]-piperidine-2-carboxyiic acid hydroxyamide; <br><br> (2B)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyi]-2-methyl-3-oxo-piperidine-2-10 carboxyiic add hydroxyamide; <br><br> (2R)-1 -{4-[2-(4-Fluorophenyi)-ethoxy]-bflnzenesu|{onyl}-2-methy1-3-oxo-piperidjne-2-carboxylic add hydroxyamide; <br><br> (2R)-2-Methyl-3-oxo-1-[4-(2-pyridin-4-yl-ethoxy)-benzenesulfonyl]-piperidine-2-carboxylic acid hydroxyamide; 15 (2B)-1-[4-(Benzothiazol-2-ylmethoxy)-benzenesulfonyl]-2-methy1-3-oxo-pipericfine- <br><br> 2-carboxylic add hydroxyamide; <br><br> (2B)-2-Methyl-3-oxo-1-[4-(5-trifluoromethyl-benzothlazol-2-ylmethoxy)-benzenesuifonyi]-piperidine-2-carboxylic acid hydroxyamide; <br><br> (2fl)-2-Methyl-3-oxo-1 tl-tetrazol-6-ylmethoxy)-benzsnesui{ony1]-pipeodjne-2-20 carboxyiic add hydroxyamide; <br><br> (2B,4§)-1-(4-Benzyloxy-benzenesulfonyl)-4-butylaminomethyl-4-hydroxy-piperidine-2-carboxylic add hydroxyamide; <br><br> (2R&gt;4§)-4-Butylaminomethyl-1-[4-{4-fluorobenzyloxy)-benzenesuHbnyl]-4-hydroxy-piperidine-2-carboxytic add hydroxyamide; <br><br> 25 (2Q,4SH-Benzylamino-1 -(4-benzyioxy-benzenesulfonyi)-piperidine-2-carboxylic add hydroxyamide; <br><br> (2R,4S)-4-Benzy1amino-1-[4-(4-fiuorobenzyioxy)-benzenesulfony1]-piperidine-2-carboxylic add hydroxyamide; <br><br> (20)-1 -[4-&lt;4-Ruorobenzytoxy)-benzenesulfonyfl-4-oxo-piperidine-2-carboxyiic acid 30 hydroxyamide; <br><br> (2B,40)-1-(4-Benzyioxy-benzenesulfonyl)-4-hydroxy-piperidine-2-carboxylicadd hydroxyamide; <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -15- <br><br> WO 98/34918 <br><br> PCT/IB98/Q0064 <br><br> -14- <br><br> (2fi,4B)-1-[4-(4-Fluorobenzyloxy)*b«nzenesulfonyl]-4-hydroxy-piperidlne-2-carboxytic acid hydroxyamide; <br><br> (2R)-1-[4-{4-Ruorobenzytoxy)-b9nzenesutfonyl]-4-methyi-piperazins-2-cart&gt;oxylic acid hydroxyamide; <br><br> S (2B.5§)-1 -[4-(4-Fluorobenzyloxy)-benzenesuifonyl]-5-hydroxy-piperidine-2- <br><br> carboxyiie acid hydroxyamide; <br><br> (2B,5§)-1-(4-Benzytoxy-benzenesu)fonyl)-5-hydroxy-piperidin»-2-carboxyttcacid hydroxyamide; <br><br> (2R,5B)-1-(4-Benzyioxy-benzenesutfony1)-5-hydroxy-piperidine-2-carboxy1icacid 10 hydroxyamide; <br><br> (2B,5R)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-5-hydroxy-piperidine-2-carboxylic acid hydroxyamide; <br><br> (25,3§}-1-(4-Benzyioxy-benzenesuifonyl)-3-hydroxy-piperidine-2-carboxylieadd hydroxyamide; <br><br> 15 (2Q,4S)-1 -{4-Benzyloxy-ben2enesu}fony))-4-hydroxy-piperidine-2-carboxylicacid hydroxyamide; <br><br> (2fi,4S)-1-[4-(4-Fiuorobenzyloxy)-benzenesulfonyl]-4-hydroxy-piperidine-2-carboxytic add hydroxyamide; <br><br> 1 -(4-8utoxy-benzenesuH6nyl)-3-(morphoHne-4-carbonyl)-piper1dine-2-cart&gt;oxyiic 20 acid hydroxyamide; <br><br> 1 -[4-{4-Fiuoro-benzyioxy)-benzenesutfonyf)-3-{morpholine-4-carbonyl)-piperidine-2-carboxyiic acid hydroxyamide; <br><br> 1 -[3-(Fluoro-benzyloxy)-propane-1 -sutfonyf]-3-(morpholinG-4-carbony1}-piperidjne-2-carboxyiic acid hydroxymide; 25 1 •(4-Butoxy-benzsnesuifonyi)-3-(pyrrolidine-1 -carbonyl)-piperidine-2-carboxyiic acid hydroxyamide; <br><br> 1 -[4-(4-Ruoro-benzytoxy)-berizene8utfonyi}-3-&lt;pyiToBdine-1 -carbonyt)-pipefkfme-2-carboxyiic acid hydroxyamide; <br><br> 1 - [3-(4-Fluoro-benzy loxy)-propane-1 -suif onyl)-3-(pyrrolidine-1 -carbonyl)-30 piperidine-2-carboxyiic acid hydroxyamide; and <br><br> 1-[4-(4-Fiuoro-banzyioxy)-benzenesulfonyi]-2-hydroxycarbamoyl-piperidine-4-carboxylic add. <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -16- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -15- <br><br> The present invention also relates to a pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, synergy with cytotoxic anticancer agents, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, sderitis, in combination with standard 5 NSAID-S and analgesics and other diseases characterized by matrix metailoproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) or (b) the inhibition of matrix metalloproteinases or the production of tumor necrosis factor (TNF) in a mammal, Including a human, comprising an amount of a compound of formula I or a pharmaceuticaily acceptable salt thereof 10 effective in such treatments and a pharmaceuticaily acceptable carrier. <br><br> The present invention also relates to a method for the inhibition of (a) matrix metalloproteinases or (b) the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of formula I or a pharmaceuticaily acceptable salt thereof. 15 The present invention also relates to a method for treating a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, sderitis, compounds of formula I may be used in combination with standard NSAICS and analgesics and in combination with cytotoxic anticancer agents, and other diseases characterized by 20 matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising administering to said mammal an amount of a compound of formula I or a pharmaceuticaily acceptable salt thereof effective in treating such a condition. <br><br> 25 <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -17- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -16- <br><br> Detaited Description of the Invention The following reaction Schemes illustrate the preparation of the compounds of the present invention. Unless otherwise indicated R', R2, R3, R4, Rs, R", R7, R*. R', n and At in the reaction Schemes and the discussion that fbiiow are delined as above. 5 Preparation 1 <br><br> 10 <br><br> R IT™. <br><br> 15 <br><br> 20 <br><br> xvi <br><br> 25 <br><br> "If <br><br> „AL°h <br><br> R1' <br><br> co.r" <br><br> A, <br><br> 8 I <br><br> s02q vi <br><br> 30 <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -18- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> 10 <br><br> -17-Preoaration 2 <br><br> h nh2 <br><br> V <br><br> C0,R25 <br><br> xviii cho c02r25 <br><br> so2q xvii <br><br> 20 12 <br><br> vi <br><br> 25 <br><br> 30 <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -19- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> 10 <br><br> 15 <br><br> 20 <br><br> -18- <br><br> Sehemo 1 <br><br> 3Xoh <br><br> COpR <br><br> 25 <br><br> SOpQ <br><br> VI <br><br> NHOH <br><br> SOgQ III <br><br> Xy <br><br> «Spir^r9 <br><br> R'ka <br><br> 25 <br><br> 30 <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -20- <br><br> WO 98/34918 <br><br> PCMB98/00064 <br><br> -19- <br><br> S9h«w3 <br><br> r26 <br><br> Cl <br><br> ^N *C00H s02q ix <br><br> 10 <br><br> 1 <br><br> h <br><br> 15 <br><br> s02q <br><br> 20 <br><br> viii <br><br> 2 <br><br> 25 <br><br> 30 <br><br> s02q vii <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -21- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> *20- <br><br> Scheme 3 <br><br> h2n h02c &gt; <br><br> Ri^N^V I o s02q xii or <br><br> 25 <br><br> 10 <br><br> 15 <br><br> H <br><br> OR25 <br><br> I o so2a xi <br><br> 20 <br><br> 25 <br><br> H <br><br> NHOH <br><br> 30 <br><br> so2a x <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -22- <br><br> wo 98/34918 <br><br> pct/ib98/00064 <br><br> -21- <br><br> 10 <br><br> Scheme 4 R' 06 _8 <br><br> R4 \ ** / <br><br> V M *£&gt; <br><br> R | tOOH R28 <br><br> XXI I 1 <br><br> 15 <br><br> J?V <br><br> I <br><br> R4 \ , <br><br> ^ Y I R H 'COOH <br><br> 20 <br><br> XXI <br><br> b <br><br> 25 <br><br> 30 <br><br> R'r« <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -23- <br><br> WO 98/34918 PCT/IB98/00064 <br><br> -22- <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> SehemB 4 eontlnuad XX <br><br> R8 <br><br> vv/ <br><br> %00H <br><br> R5 <br><br> R« v /V <br><br> % v # <br><br> Rl T^N^HOH <br><br> ■ r <br><br> 0 <br><br> S0eQ <br><br> 30 <br><br> XIII <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -24- <br><br> WO 98/34918 <br><br> PCMB98/00064 <br><br> -23- <br><br> Scheme 5 R« l"/ <br><br> -J-A) fTA* ,0 <br><br> R I ..tOOR'0 Re <br><br> 10 <br><br> 15 <br><br> 20 <br><br> 25 <br><br> XXV t 1 <br><br> R31 <br><br> _R* <br><br> R \ g <br><br> XXV <br><br> R31 D® <br><br> sfe. <br><br> 30 <br><br> XX [V <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -25- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -24- <br><br> Scheme 5 continued XXIV <br><br> 10 <br><br> Rn <br><br> «V J. / <br><br> J t00R,# S0tQ <br><br> XXIII <br><br> 15 <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -26- <br><br> WO 98/34918 <br><br> PCMB98/00064 <br><br> -25- <br><br> Preparation 1 refers to the preparation of intermediates of the formula VI. Compounds of the formula VI are converted to compounds of the formula I according to the methods of Scheme 1. The starting materials of formula XVI can be prepared according to methods well known to those of ordinary skill in the art. <br><br> 5 In reaction 1 of Preparation i, the compound of formula XV! is converted to the corresponding hydroxy ester compound of formula VI by first reacting XVI with an aryisulfonylhaiide in the presence of tiiethyt amine and an aprotic solvent, such as methylene chloride, tetrahydrofuran or dioxane, at a temperature between about 20° C to about 30° C, preferably at room temperature. The compound so formed is further 10 reacted with a compound of the formula <br><br> R9 COaR25 <br><br> T <br><br> Br <br><br> 15 wherein R28 is carbobenzyioxy, (C,-C8)alkyl, benzyl, ally! or tert-butyi, in the presence of sodium hexamethyldisilazane and a tetrahydrofuran-dimethyiformamide solvent mixture at a temperature between about -20°C to about 20°C, preferably about 0°C, to form the hydroxy ester compound of formula VI. <br><br> Preparation 2 refers to an alternate method of preparing compounds of the 20 formula VI. The starting materials of formula XVIII can be prepared according to methods well known to those of ordinary skill in the art. In reaction 1 of Preparation 2, the amine compound of formula XVIII, wherein RM is as defined above, is converted to the corresponding arylsulfonyi amine compound of formula XVII by (1) reacting XVIII with an aryisulfonylhaiide in the presence of triethyiamine and an aprotic solvent, such 25 as methylene chloride, tetrahydrofuran, or dioxane, at a temperature between about 20°C to about 30°C, preferably at room temperature, (2) reacting the compound so formed with a compound of the formula <br><br> 30 <br><br> in the presence of sodium hexamethyidisiiazane and a tetrahydrofuran-dimethylformamide solvent mixture at a temperature between about -20 °C to about 204C, preferably about 0°C, and (3) further reacting the compound so formed with ozone in a methylene chioride-methanol solution at a temperature between about -90°C <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -27- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -26- <br><br> to about -70°C, preferably about -78°C. The unstable ozonlde compound so formed is then reacted with triphenylphosphine to form the aryisulfonyf amine compound formula XVII. In Reaction 2 of Preparation g, the arylsulfonyl amine compound of formula XVII is converted to the corresponding hydroxy ester compound of formula VI 5 by reacting XVII with a compound of the formula <br><br> 10 wherein W is lithium, magnesium, copper or chromium. <br><br> Scheme 1 refers to the preparation of compounds of the formula II, which are compounds of the formula I, wherein X and Y are carbon; R4, R6 and R7 are hydrogen; and the dashed line between X and Y Is absent In reaction 1 of Scheme J, the compound of formula VI, wherein the R* protecting group is carbobenzyioxy, (C,-Ce) 15 alkyl, benzyl, ally! or tert-butyi, is converted to the corresponding morpholinone compound of formula V by lactonizaiion and subsequent Claisen rearrangement of the compound of formula VI. The reaction is facilitated by the removal of the RM protecting group from the compound of formula VI and is carried out under conditions appropriate for that particular R" protecting group in use. Such conditions include: (a) treatment 20 with hydrogen and a hydrogsnation catalyst, such as 10% palladium on carbon, where R28 is carbobenzyioxy, (b) saponification where R28 is lower alkyl, (c) hydrogenolysis where R25 Is benzyl, (d) treatment with a strong acid, such as trifluoroacetic add or hydrochloric add, where R* is tert-butyi, or (e) treatment with tributyitinhydride and acetic add in the presence of catalytic bis(triphenyiphosphine) palladium (II) chloride 25 where R2® is aUyi. <br><br> In reaction 2 of Scheme i, the morpholinone compound of formula V is converted to the carboxyiic add compound of formula IV by reacting V with lithium hexamethyldisiiazane in an aprotic solvent, such as tstrahydrofuran, at a temperature between about -90°C to about -70°C, preferably about -78°C. Trimethylsilyl chloride 30 is then added to the reaction mixture and the solvent, tetrahydrofuran, is removed in vacuo and replaced with toluene. The resuling reaction mixture is heated to a temperature between about 100°C to about 120°C, preferably about 110°C, and treated with hydrochloric acid to form the carboxyiic add compound of formula IV. <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -28 <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -27- <br><br> ln reaction 3 of Scheme i, the carboxyiic acid compound of formula IV is converted to the corresponding hydroxamic acid compound of formula III by treating IV with 1 -(3-dimethyiaminopropyl)-3-«thyicart&gt;odiimide and 1-hydroxybenztriazole in a polar solvent, such as dimethyiformamide, followed by the addition of hydroxytamine 5 to the reaction mixture after a time period between about 15 minutes to about 1 hour, preferably about 30 minutes. The hydroxylamine is preferably generated }q from a salt form, such as hydroxylamine hydrochloride, in the presence of a base, such as N-methylmorphoiine. Alternatively, a protected derivative of hydroxylamine or its salt form, where the hydroxy! group is protected as a tert-butyi, benzyl or ally! ether, may 10 be used in the presence of (benzotriazol-1 -yloxy)tris(dimethyiamino) phosphonium hexafluorphosphate and a base, such as N-methyimorpholine. Removal of the hydroxylamine protecting group is carried out by hydrogenolysls for a benzyl protecting group or treatment with a strong acid, such as trifluoroacetic add, for a tert-butyi protecting group. The ally! protecting group may be removed by treatment with 15 tributyltinhydride and acetic add in the presence of catalytic bis(triphenyiphosphine) palladium (II) chloride. N,0-bls(4-methoxybenzyi)hydroxyiamine may also be used as the protected hydroxylamine derivative where deprotection is achieved using a mixture of methanesuHonic add and trifluoroacetic add. <br><br> In reaction 4 of Scheme i, the hydroxamic acid compound of formula III is 20 converted, if desired, to the corresponding piperidine compound of formula II by treating III with hydrogen and a hydrogenation catayst, such a 10% palladium on carbon. <br><br> Scheme 2 refers to the preparation of compounds of the formula VII, which are compound of the formula I wherein Y is nitrogen; X is carbon; R\ R2, R3, R\ R7 and R" 25 are hydrogen, and R' is absent. The starting materials of formula IX can be prepared according to methods well known to those of ordinary skill in the art. In reaction 1 of Scheme 2. the arylsuifonyipiperazine compound of formula IX, wherein RM Is carbobenzyioxy, benzyl or carbotertbutyloxy, is converted to the compound of formula VIII by reacting IX with a protected derivative of hydroxylamine of the formula 30 R,7ONH,«HCI <br><br> wherein R27 is tertbutyl, benzyl or allyi, in the presence of dlcydohexyicarbodiimide, dimethylaminopyridine and an aprotic solvent, such as methylene chloride. The RM protecting group is chosen such that it may be selectively removed in the presence of an without loss of the R27 protecting group, therefore, RM cannot be the same as R27. <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -29- <br><br> Wo 98/34918 <br><br> PCT/IB98/00064 <br><br> -28- <br><br> Removal of the R20 protecting group from the compound of formula IX is carried out under conditions appropriate for that particular RM protecting group in use. Such conditions include; (a) treatment with a hydrogen and a hydrogenation catalyst, such as 10% palladium on carbon, where RM is carbobenzyioxy, (b) hydrogenolysis where 5 R2# is benzyl or (c) treatment with a strong add, such as trifluoroacetic acid or hydrochloric acid where R2* is carbotertbutyioxy. <br><br> In reaction 2 of Scheme 2. the compound of formula VIII is converted to the corresponding hydroxamic acid compound of formula VII, wherein R® is hydrogen or (C,-C8)aJkyl, by reacting, if desired, VIII with an aikylhalide when R8 is (C,-C8)aJkyi. 0 Subsequent removal of the R27 hydroxylamine protecting group is carried out by hydrogenolysis for a benzyl protecting group or treatment with a strong acid, such as trifluoroacetic add, for a tert-butyi protecting group. The aliyi protecting group may be removed by treatment with tributyltinhydride and acetic add in the presence of catalytic bis(triphenylphosphine) palladium (II) chloride. <br><br> 5 Scheme 3 refers to the preparation of compounds of the formula X, which are compounds of the formula I wherein Y is nitrogen; X is carbon; R2, R7, R* and R* are hydrogen; R3 and R4 taken together are carbonyl; R8 is hydrogen, and R* is absent. In reaction 1 of Scheme 3, the aryisulfonyiamine compound of formula XII, wherein R28 is as defined above, is converted to the corresponding piperaane compound of formula 0 XI by reacting XII with a carbodiimide and a base, such as triethyiamine. The compound of formula XI is further reacted to give the hydroxamic add compound of formula X according to the procedure described above in reaction 3 of Scheme 1. <br><br> Scheme 4 refers to the preparation of compounds of the formula XIII. The starting materials of formula XVIII can be prepared according to methods well known 5 to those of ordinary skill In the art. Compounds of the formula XIII are compounds of the formula i wherein X is carbon, and the dotted line between X and Y is absent tn reaction 1 of Scheme 4, removal of the R1* protecting group and subsequent reductive amination of the compound of formula XXII, wherein Y is oxygen, sulfur or carbon, to give the corresponding imine compound of formula XXI is carried out under conditions 10 appropriate for that particular R2* protecting group in use. Such conditions include those used above for removal of the R" protecting group In reaction 1 of Scheme £. <br><br> In reaction 2 of Scheme 4, the imine compound of formula XXI Is converted to the corresponding piperidtne compound of formula XX by reacting XXI with a nudeophiie of the formula R2M wherein M Is lithium, magnesium haUde or cerium <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -30- <br><br> WO 98/34918 <br><br> PCMB98/00064 <br><br> -29- <br><br> halide. The reaction is carried out in ether solvents, such as diethyl ether or tetrahydrofuran, ait a temperature between about •78°C to about 0°C, preferably about -70°C. <br><br> In reaction 3 of Scheme 4, the suttonation of the piperidine compound of 5 formula XX to given the corresponding aryisulfonytpiperidine compound of formula XIX is carried out by reacting XX with an aryisulfonylhaiide in the presence of triethyiamine and an aprotic solvent, such as methylene chloride, tetrahydrofuran or dioxane, at a temperature between about 20°C to about 30°C, preferably at room temperature. <br><br> In reaction 4 of Schema 4, the arytsutfonyipiperidine compound of formula XIX 0 is converted to the hydroxamic acid compound of formula XIII according to the procedure described above in reaction 3 of Scheme 1. <br><br> Scheme 5 refers to the preparation of compounds of the formula XIV, which are compounds of formula I wherein Y is nitrogen, X is carbon, the dotted line between X and Y is absent, R5 is hydrogen and R* is absent. In reaction 1 of Scheme §, the 5 compound of formula XXVI, wherein the RM and RS1 protecting groups are each independently selected from the group consisting of carbobenzyioxy, benzyl and carbotertbutyioxy and R30 is carbobenzyioxy, (C,-CB)alkyl, benzyl, ally! or tert-butyi, is converted to the corresponding imine compound of formula XXV by the removal of the R2* protecting group and subsequent reductive asnination of the compound of formula 0 XXVI. The R" protecting group is chosen such that it may be selectively removed in the presence of and without loss of the R3' protecting group. Removal of the R2* protecting group from the compound of formula XXVI is carried out under conditions appropriate for that particular R29 protecting group in use which will not affect the R31 protecting group. Such conditions include; (a) treatment with hydrogen and a !5 hydrogenation catalyst, such as 10% palladium on carbon, where R2* is carbobenzyioxy and R3' is tert-butyi, (b) saponification where R3* is (C,-C,)alkyi and R3' is tert-butyi, (c) hydrogenolysis where R2* is benzyl and R3&gt; is (C,-C8) alkyl or tert-butyi, (d) treatment with a strong acid such as trifluoroacetic acid or hydrochloric acid where R2* is tert-butyi and R31 is (C,-Cfl)alkyil benzyl or ally!, or (e) treatment with tributyltinhydride and acetic 10 acid in the presence of catalytic bis(triphenyiphosphine) palladium (II) chloride where R2* is ally! and R11 is (C,-C,)alkyl, benzyl or tert-butyi. The R30 protective group may be selected such that it is removed in the same reaction step as the R2* protecting group. <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -31 <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -30- <br><br> ln reaction 2 of Scheme jg, the imine compound of formula XXV is converted to the corresponding compound of formula XXIV by reacting XXV with a nudeophile of the formula R2M wherein M is lithium, magnesium haiide or calcium halide. The reaction is carried out in ether solvents, such as diethyl ether or tetrahydrofuran, at a 5 temperature between about -78°C to about 0°C, preferably about -70°C. <br><br> In reaction 3 of Scheme §, the suHonation of the piperidine compound of formula XXIV to give the corresponding aryisutfonyipiperidine compound of formula III is carried out according to the procedure described above in reaction 3 of Scheme 4. <br><br> In reaction 4 of Scheme §, the aryisutfonyipiperidine compound of formula XXIII 10 is converted to the hydroxamic add compound of formula XIV by (1) removing the R*°, if needed, and R" protecting groups from XXIII followed by (2) reacting XXIII according to the procedure described above in reaction 3 of Scheme 1. Removal of the RJ0 and RJ1 protecting groups from the compound of formula XXIII is carried out under conditions appropriate for that particular R*° and R" protecting group in use. Such 15 conditions include those used above for removal of the R26 protecting group in reaction 1 of Scheme 1. <br><br> Pharmaceuticaily acceptable salts of the addle compounds of the invention are salts formed with bases, namely cationic salts such as alkali and alkaline earth metal salts, such as sodium, lithium, potassium, caldum, magnesium, as well as ammonium 20 slats, such as ammonium, trimethyi-ammonium, diethylammonium, and tris-(hydroxymethyi)-methyiammonium salts. <br><br> Similarly acid addition salts, such as of mineral acids, organic carboxyiic and organic sulfonic acids e.g. hydrochloric add, methanesulfonic add, maleic add, are also possible provided a basic group, such as pyridyl, constitutes part of the structure. 25 The ability of the compounds of formula I or their pharmaceuticaily acceptable salts (the compounds of the invention) to inhibit matrix metalloproteinases or the production of tumor necrosis factor (TNF) and, consequently, demonstrate their effectiveness for treating diseases characterized by matrix metalloproteinase or the production of tumor necrosis factor is shown by the following iQ vitro assay tests. <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -32 <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -31-Pip|(?qi9?J <br><br> Inhibition of Human CoHaaenage fMMP-H Human recombinant collagenase is activated with trypsin using the following ratio: 10 fjg trypsin per 100 jjq of collagenase. The trypsin and collagenase are 5 incubated at room temperature for 10 minutes then a five fold excess (50 /*g/10 fig trypsin) of soybean trypsin inhibitor is added. <br><br> 10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted using the following Scheme: <br><br> 10mM &gt; 120//M &gt; 12//M &gt; 1.2//M &gt; 0.12 <br><br> 10 Twenty-five microliters of each concentration is then added in triplicate to appropriate wells of a 96 well microfluor plate. The final concentration of inhibitor will be a 1:4 dilution after addition of enzyme and substrate. Positive controls (enzyme, no inhibitor) are set up in wells D1-D6 and blanks (no enzyme, no inhibitors) are set in wells 07-012. <br><br> 16 Collagenase is diluted to 400ng/ml and 25 (A is then added to appropriate wells of the microfluor plate. Final concentration of collagenase in the assay is 100 ng/mi. <br><br> Substrate (DNP-Pro-Cha-Gly-Cyt(Me)-His-Alat-Lys(NMA)-NHz) is made as aS mM stock in dimethyl sulfoxide and then diluted to 20 /iM in assay buffer. The assay is Initiated by the addition of 50 jA substrate per well of the microfluor piate to give a final 20 concentration of 10 fM. <br><br> Fluorescence readings (360 nM excitation, 460 nm emission) were taken at time 0 and then at 20 minute intervals. The assay is conducted at room temperature with a typical assay time of 3 hours. <br><br> Fluorescence vs time is then plotted for both the blank and collagenase 25 containing samples (data from triplicate determinations is averaged). A time point that provides a good signal (the blank) and that is on a linear part of the curve (usually around 120 minutes) is chosen to determine ICM values. The zero time is used as a blank for each compound at each concentration and these values are subtracted from the 120 minute data. Data is plotted as inhibitor concentration vs % control (inhibitor 30 fluorescence divided by fluorescence of collagenase alone x 100). IC^'s are determined from the concentration of inhibitor that gives a signal that is 50% of the control. <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -33- <br><br> Wo 98/34918 <br><br> PCT/IB98/00064 <br><br> -32- <br><br> If IC,0's are reported to be &lt;0.03 //M then the inhibitors are assayed at concentrations of 0.3 (jM, 0.03 fjM, 0.03 pM and 0.003 pM. <br><br> Inhibition of Qelatinase (MMP-21 <br><br> Inhibition of getatinase activity is assayed using the Dnp-Pro-Cha-Giy-Cys(Me)-5 His-Ala-Lys(NMA)-NH2 substrate (10 pM) under the same conditions as inhibition of human collagenase (MMP-1). <br><br> 72kD gelaiinase is activated with 1 mM APMA (p-aminophenyt mercuric acetate) for 15 hours at 4°C and is diluted to give a final concentration in the assay of 100 mg/ml. Inhibitors are diluted as for inhibition of human collagenase (MMP-1) to give 0 final concentrations in the assay of 30 f/M, 3 f/M, 0.3 /jM and 0.03 /jM. Each concentration is done in triplicate. <br><br> Fluorescence readings (360 nm excitation, 460 emission) are taken at time zero and then at 20 minutes intervals for 4 hours. <br><br> ICjo's are determined as per inhibition of human collagenase (MMP-1). If ICgo's 5 are reported to be less than 0.03 /jM, then the inhibitors are assayed at final concentrations of 0.3 pM, 0.03 pM, 0.003 pM and 0.003 //M. <br><br> inhibition of Stromeivsln Activity (MMP-3) <br><br> Inhibition of stromeiysin activity is based on a modified spectrophotometric assay described by Weingarten and Feder (Weingarten, H. and Feder, J., !0 Spectrophotometric Assay for Vertebrate Collagenase, Anal. Biochem. 147. 437-440 (1985)). Hydrolysis of the thio peptolide substrate [Ac-Pro-Leu-Gly-SCH[CH2CH(CH3)j]CO-Leu-Qly-OC2H5] yields a mercaptan fragment that can be monitored in the presence of EBman's reagent. <br><br> Human recombinant prostrometysin is activated with trypsin using a ratio of 1 pi !5 of a 10 mg/ml trypsin stock par 26 pg of stromelysin. The trypsin and stromeiysln are incubated at 37°C for 15 minutes followed by 10 fA of 10 mg/ml soybean trypsin inhibitor for 10 minutes at 37°C for 10 minutes at 37°C to quench trypsin activity. <br><br> Assays are conducted in a total volume of 250 pi of assay buffer (200 mM sodium chloride, 50 mM MES, and 10 mM calcium chloride, pH 6.0) in 96-well microliter 10 plates. Activated stromelysin is diluted in assay buffer to 25 pg/ml. Ellman's reagent (3-Carboxy-4-nitrophenyl disulfide) is made as a 1M stock in dimethyl formamide and diluted to 5 mM in assay buffer with 50 (A per wefl yielding at 1 mM final concentration. <br><br> 10 mM stock solutions of inhibitors are made in dimethyl sulfoxide and diluted serially in assay buffer such that addition of 50 /jL to the appropriate wells yields final <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -34- <br><br> WO 98/34918 <br><br> FCMB98/00064 <br><br> -33- <br><br> concentrations of 3 pM, 0.3 pM, 0.003 pM, and 0.0003 pM. All conditions are completed in triplicate. <br><br> A 300 mM dimethyl sulfoxide stock solution of the peptide substrate is diluted to 15 mM in assay buffer and the assay is initiated by addition of 50 pi to each well to 5 give a final concentration of 3 mM substrate. Blanks consist of the peptide substrate and Ellman's reagent without the enzyme. Product formation was monitored at 405 nm with a Molecular Devices UVmax plate reader. <br><br> IC50 values were determined in the same manner as for collagenase. <br><br> Inhibition of MMP-13 <br><br> 0 Human recombinant MMP-13 is activated with 2mM APMA (p-aminophenyl mercuric acetate) for 1.5 hours, at 37°C and is diluted to 400 mg/ml in assay buffer (50 mM Tris, pH 7.5,200 mM sodium chloride, 5mM calcium chloride, 20pM zinc chloride, 0.02% brij). Twenty-five mieroltters of diluted enzyme is added per well of a 96 weU microfluor plate. The enzyme is then diluted in a 1:4 ratio in the assay by the addition 5 of inhibitor and substrate to give a final concentration in the assay of 100 mg/ml. <br><br> 10 mM stock solutions of inhibitors are made up in dimethyl sulfoxide and then diluted in assay buffer as per the inhibitor dilution scheme for inhibition of human collagenase (MMP-1): Twenty-five microliters of each concentration is added in triplicate to the microfluor plate. The final concentrations in the assay are 30 pM, 3pM, !0 0.3 pM, and 0.03 pM. <br><br> Substrate (Dnp-Pro-Cha-Gly-Cys(Me)-His-AJa-Lys(NMA)-NH2) is prepared as for inhibition of human collagenase (MMP-1) and 50 pi is added to each well to give a final assay concentration of 10 pM. Fluorescence readings (360 nM excitation; 450 emission) are taken at time 0 and every 5 minutes for 1 hour. <br><br> !5 Positive controls consist of enzyme and substrate with no inhibitor and blanks consist of substrate only. <br><br> IC50's are determined as per inhibition of human collagenase (MMP-1). If ICk's are reported to be less than 0.03 pM, inhibitors are then assayed at final concentrations of 0.3 pM. 0.03 pM, 0.003 pM and 0.0003 pM. &gt;0 Inhibition of TNF Production <br><br> The ability of the compounds or the pharmaceuticaily acceptable salts thereof to inhibit the production of TNF and, consequently, demonstrate their effectiveness for treating diseases involving the production of TNF is shown by the following jQ vitro assay: <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -35- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -34- <br><br> Human mononudear ceils wars isolated from anti-coaguiated human blood using a one-step Ficoll-hypaque separation technique. (2) The mononuclear cells were washed three times in Hanks balanced salt solution (HBSS) with divalent cations and resuspended to a density of 2 x 10s /ml in HBSS containing 1% BSA. Differential 5 counts determined using the Abbott Cell Dyn 3500 analyzer indicated that monocytes ranged from 17 to 24% of the total cells In these preparations. <br><br> 180*/ of the cell suspension was allquoted into fiate bottom 96 well plates (Costar). Additions of compounds and LPS (100ng/ml final concentration) gave a final volume of 20Q/ul. All conditions were performed in triplicate. After a four hour 10 incubation at 37°C in an humidified C02 incubator, plates were removed and centrifuged (10 minutes at approximately 250 x g) and the supematants removed and assayed for TNFo using the R&amp;D EUSA Kit <br><br> For administration to mammals, including humans, for the inhibition of matrix metalloproteinases or the production of tumor necrosis factor (TNF), a variety of 15 conventional routes may be used including orally, parenteraliy and topically. In general, the compound of the invention will be administered orally or parenteraliy at dosages between about 0.1 and 25 mg/kg body weight of the subject to be treated per day, preferably from about 0.3 to 5 mg/kg. However, some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person 20 responsible for administration will, in any event, determine the appropriate dose for the individual subject. <br><br> The compounds of the invention can be administered in a wide variety of different dosage forms. In general, the therapeutically effective compounds of this invention are present in such dosage forms at concentration levels ranging from about 25 5.0% to about 70% by weight. <br><br> For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dicaJcium phosphate and glycine may be employed along with various disintegrants such as starch (and preferably com, potato or tapioca starch), alginic add and certain complex silicates, 30 together with granulation binders like polyvinylpyrrolidone, sucrose, gelation and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tabiettlng purposes. Solid compositions of a similar type may also be employed as fillers in gelatin capsules; preferred materials in this connection also include lactose or milk sugar as wed as high molecular weight <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -36 <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -35- <br><br> polyethytene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene 5 glycol, glycerin and various Hke combinations thereof. In the case of animals, they are advantageously contained in an animal feed or drinking water in a concentration of 5-5000 ppm, preferably 25 to 500 ppm. <br><br> For parenteral administration (intramuscular, intraperitoneal, subcutaneous and intravenous use) a sterile injectable solution of the active ingredient is usually prepared. 0 Solutions of a therapeutic compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably adjusted and buffered, preferably at a pH of greater than 8, if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable intravenous injection purposes. The oily solutions are suitable for intraarticular, 5 intramuscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well known to those skilled in the art. In the case of animals, compounds can be administered intramuscularly or subcutaneously at dosage levels of about 0.1 to 50 mg/kg/day, advantageously 0.2 to 10 mg/kg/day given in a single dose or up to !0 3 divided doses. <br><br> The present invention is illustrated by the following examples, but it is not limited to the details thereof. <br><br> EXAMPUS1 <br><br> &lt;2R. 4RW1 -(4-Msthoicv-benzenesuHonviy-4-(ptoerazine-1 «carbonvl V-pjperidine-2-!5 carboxvllc acid hvdroxvamide hydrochloride <br><br> (a) To a stirred, cold (-78 °C) solution of (2g)-2-benzyloxycarbonyiamino-pentanedioic add 1-tert-butyi ester 5-methyl ester (5.6g, 15.9 mmoi), prepared as described in J. Org. Chem., §§. 1711-1721 (1990) and J. Med. Chem., 32,73-85 (1996), in 30 ml of tetrahydrofuran was added lithium bis(trimethyisilyl)amide (40 mL, 1 M in 10 tetrahydrofuran, 39.8 mmoi). The resulting mixture was stirred for 1 hour at-45 °C and then recooled to -78 °C. Ally! bromide (5.2 mL, 63.7 mmoi) was then added. After 2 hours the reaction was quenched by the addition of 1 M aqueous hydrogen chloride at -78 °C. The mixture was then extracted with diethyl ether. The combined ethereal <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -37- <br><br> WO 98/34918 <br><br> PCMB98/00064 <br><br> -36- <br><br> extracts were washed with brine and the mixture was dried over sodium sulfate. After filtration and concentration of the filtrate, the crude product was purified by silica gel chromatography (elution with 1:5 ethyl acetata/hexanes) to provide (2jB,4B)-4-allyl-2-benzyloxycarbonyiamino-pentanedioic acid 1-tert-butyi ester 5-methyi ester. <br><br> 5 (b) Ozone gas was bubbled through a stirred, cold (-78 °C) solution of (2B.4BM-allyt-2-benzyioxycarbonyiamino-pentanedioic acid 1-tert-butyi ester 5-methyl ester (5.0 g, 12.8 mmoi) in 100 mL of 10:1 methanol/methylene chloride, and 0.73 mL of acetic acid until a blue color persisted. Nitrogen gas was then bubbled through the solution until the blue color dissipated. The mixture was warmed to ambient temperature and 10 dimethyl sulfide (2.8 mL, 3.83 mmoi) was added. The mixture was stirred for 48 hours, diluted with methylene chloride, and washed with 10% aqueous sodium carbonate, brine, and the mixture was dried over sodium sulfate. Filtration and concentration of the filtrate provided (23,4§)-6-methoxy-piperidine-1,2,4-tricarboxyiic add 1 -benzyl ester 2-tert-butyi ester 4-methyi ester as a dear oil, which was used in the subsequent step 15 without purification. <br><br> (c) A mixture of {23,4§}-6-methoxy-pip«idine-1,2,4-tricarboxyiic add 1 -benzyl ester 2-tert-butyl ester 4-methyi ester (4.85 g, 11.9 mmoi) and 10% palladium on carbon (600 mg) in 100 mL of ethanoi was shaken under a 45 psi atmosphere of hydrogen gas for 1.5 hours. The mixture was filtered through nylon and the filtrate was concentrated to <br><br> 20 provide (2R,4R)-piperidine-2,4-dicarboxyHc add 2-tert-butyl ester 4-methyi ester as Ught yellow oii, which was used in the subsequent step without further purification. <br><br> (d) To a stirred, cold (0 °C) solution of (2B,4B)-piperidine-2,4-dicarboxyiic acid 2-tert-butyi ester 4-methyi ester (2.7 g, 11.1 mmoi) and triethylamine (4.6 mi, 33.3 mmoi) in 30 mL of methylene chloride was added 4-methoxy-benzenesuifonyl chloride (2.3 g, <br><br> 25 11.1 mmoi). The mixture was warmed to ambient temperature and stirred for 4 hours. The reaction was quenched by the addition of aqueous ammonium chloride and the mixture was extracted with ethyl acetate. The combined organic extracts were washed with brine, and the organic mixture was dried over sodium sulfate. After filtration and concentration of the filtrate, the resulting crude product was purified by silica gel 30 chromatography (elution with 3:8 ethyl acetate/hexanes) to provide (2Q,4R)-1-(4-methoxy-benzenesutfonyl)-piperidine-2,4-dicarboxyiic add 2-tert-butyi ester 4-methyi ester. <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -38- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -37- <br><br> (e) To a stirred, cold (0 °C) solution of (2R.4BH -(4-methoxy-benzenesulfonyl)-piperidine-2,4-dicarboxy1ic acid 2-tert-butyl ester 4-methyl ester (4.4 g, 10.6 mmoi) in 30 mL of methylene chloride was added 10 mL of trifluoroacetic acid dropwise. The mixture was stirred for 1 hour at 0 °C and for 8 hours at ambient temperature. <br><br> 5 Concentration provided (2B,4B)-1-(4-methoxy-benzenesulfonyl)-piperidine-2,4-dicarboxytic acid 4-methyl ester, which was used in the subsequent step without purification. <br><br> (f) To a stirred solution of (2B.4B)-1-(4-methoxy-benzenesuifonyl)-piperidine-2,4-dicarboxylic acid 4-methyl ester (4.4 g, 12.3 mmoi), O-benzythydroxylamine <br><br> 10 hydrochloride (2.15 g, 13.5 mmoi), and triethylamine (5.15 mL, 36.9 mmoi) was added benzotriazol-1 •yioxy-tris(dimethylamino)phosphonium hexafluorophosphate (6.0 g, 12.3 mmoi) at ambient temperature. The resulting mixture was stirred for 24 hours. The mixture was diluted with ethyl acetate and washed with 1 M aqueous hydrogen chloride, aqueous sodium bicarbonate, and brine. The organic mixture was dried over 15 magnesium sulfate, filtered, and the filtrate was concentrated. The crude residue was purified by silica gel chromatography (elution with 5% methanol in methytene chloride) to provide (2Bl4Q}-2-benzyloxycarbamoyl-1-{4-methoxy-benzenesulfonyl)-plperidine- <br><br> 4-carboxyiic acid methyl ester as a colorless solid. <br><br> (g) To a stirred cold (0 ° C) solution of (2B,4R)-2-benzyioxycarbamoyM -(4-methoxy-20 benzenesuifonyl)-piperidine-4-carboxyiic acid methyl ester (4.0 g, 8.6 mmoi) in 10 mL <br><br> of 9:1 methanol/water was added lithium hydroxide monohydrate (1.8 g, 43 mmoi). The mixture was stirred for 2 hours before Amberlite IR-120 resin (96 g) was added. After 15 minutes, the mixture was filtered and the filtrate was concentrated to give (2B,4E)-2-benzyloxycarbamoyl-1 -(4-methoxy-benzenesutfonyi)-piperidine-4-cart&gt;oxyiicacjd,which 25 was used in the subsequent reaction without purification. <br><br> (h) To a stirred solution of (2B,4fi)-2-benzyioxycarbamoyl-1 -(4-methoxy-benzenesulfony()-piperidine-4-carboxyiie add (500 mg, 1.11 mmoi), tert-butyloxycarbonyl piperazine (226 mg, 1.21 mmoi), and triethylamine (0.47 mL, 3.33 mmoi) was added benzotriazol-1-yloxy-tris(dimethylamino)phosphonium <br><br> 30 hexafluorophosphate (535 mg, 1.21 mmoi) at ambient temperature. The resulting mixture was stirred for 24 hours. The mixture was diluted with ethyl acetate and washed with 1 M aqueous hydrogen chloride, aqueous sodium bicarbonate, and brine. <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -39 <br><br> WO 98/34918 <br><br> PCT/EB98/00064 <br><br> •38* <br><br> The organic mixture was dried over magnesium sulfate, filtered, and the filtrate was concentrated. The crude residue was purified by silica gel chromatography (elution with 2% methanol in methylene chloride) to provide (2Q,4Q)-4-[2-benzyioxycarbamoyi-1 • (4-methoxy-benzenesulfonyl)-piperidin®-4-carbonyl]-plperazine-1 -carboxyiic acid tert-5 butyl ester as a colorless solid. <br><br> (i) A mixture of (2B,4R)-4-[2-benzyloxycarbamoyl-1 -(4~methoxy-benzene- sulfonyi)-piperidine-4-carbonyl]-pipefazine-1 -carboxyiic acid tert-butyi ester (500 mg, 0.81 mmoi) and 5% palladium on barium sulfate (250 mg) in 10 mL of methanol was shaken under a 40 psi atmosphere of hydrogen gas for 1.5 hours. Filtration through nylon and 10 concentration of the filtrate provided {2Q,4Q)-4-[2-hydroxycarbamoyM-(4-methoxy-benzenesulfonyl)-piperidine-4-carbonyl]-piperazine-1-carboxylic acid tert-butyi ester as a colorless solid, which was used in the subsequent step without purification. <br><br> (j) Hydrogen chloride gas was bubbled through a cold (0° C) solution of (2JB.4QH-[2-hydroxycarbamoyM -(4-methoxy-beraenesulfonyl}-piperkfine-4-carbonyi]-piperazine-1 -15 carboxyiic add tert-butyi ester (420 mg, 0.8 mmoi) for 10 minutes. After an additional 20 minutes the mixture was concentrated to provide (2R, 4RJ-1 -(4-methoxy-benzenesulfonyl)-4-(piperazine&gt;1-carbonyl)-piperidine-2-carboxylic add hydroxyamide hydrochloride as a colorless solid: Mass spectrum (atmospheric pressure chemical ionization; basic mode) m&amp; (M+H) 427,366; 'H NMR (dimethyl sulfoxide^, 400 MHz, 20 ppm) 6 10.70 (bd, 1 H, J = 2.7 Hz). 9.06 (bs, 2 H), 8.84 (bs, 1 H), 7.70 (dd, 2 H, J ■ 8.9,2.9 Hz), 7.06 (dd, 2 H, J - 8.9,2.9 Hz), 4.42 (bs, 1 H), 3.80 (s, 3 H), 3.80-3.20 (m, 6 H), 3.04 (m, 4 H), 2.76 (m, 1 H), 1.79 (bd, 1 H, jJ « 13.5 Hz), 1.52 (bd, 1 H, J = 12.6 Hz), 1.32 (m, 1 H) 1.14 (m 1H). <br><br> Example 2 <br><br> 25 (2B.4R&gt;-1 -f3»f4-FluorophenoxvVpropane-1 -sulfonvH-2-hvdroxvcarbamovl- <br><br> ptoeridtne-4-carboxvHc acid methvl eater <br><br> (a) To astirred solution of (2Q,4B)-piparidine-2,4-dicarboxyiic add 2-tert-butvl ester 4-methyl ester (920 mg, 3.78 mmoi) and triethylamine (1.58ml, 11.3 mmoi) in 10 mL of methylene chloride was added a solution of 3-(4-fluorophenoxy)-propane-1-30 sulfonyi chloride (1.05 g, 4.16 mmoi) In 2 mL of methylene chloride under a nitrogen atmosphere. The mixture was stirred for 16 hours at ambient temperature (22 °C), then <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -40- <br><br> WO 98/34918 <br><br> PCT/1B98/00064 <br><br> -39- <br><br> diluted with 20 mL of 1 N hydrochloric acid and 20 mL of methylene chloride. The organic layer was removed and washed with brine and dried over sodium sulfate. Filtration and concentration of the filtrate gave 2.8 g of a yellow oil, which was purified by flash chromatography (3:2 hexanes/ethyt acetate elution) to give 1.15 g (2FJ,4R)-1 -[3-5 (4-fluoro-phenoxy)-propane-1 -sulfonyl]-piperidine-2,4-dicarboxyiic acid 2-tert-butyl ester 4-methyl ester of as a yellow oil. <br><br> (b) To a stirred, cold (0 °C) solution of (2B,4g)-1-[3-(4-fluorophenoxy)-propane-1-sulfonyl]-piperidine-2,4-dicarboxylic add 2-tert-butvt ester 4-methyl ester (1.15 g, 2.5 mmoi) in 10 mL of methylene chloride was added 10 mL of trifluroacetic add. The <br><br> 10 mixture was allowed warm to ambient temperature (22 °C) over 16 hours. The mixture was concentrated in vacuo to give 970 mg of crude (2B,4R)-1-[3-(4-fluorophenoxy)-propane-1-sutfonyf]-piperidine-2,4-dicarboxylic acid 4-methyl ester as a orange solid. <br><br> (c) To a stirred solution of (2fl,4R)-1 -[3-(4-fluorophenoxy)-propane-1 -suffonyl]-piperidine-2,4-dicart&gt;oxytic add 4-methyl ester (970 mg, 2.4 mmoi) in 5 mLof methylene <br><br> 15 chloride was added triethylamine (1.0 ml_ 7.2 mmoi) and Q-benzylhydroxytamine hydrochloride (410 mg, 2.64 mmoi) at ambient temperature (22 °C). To the resulting solution was added benzotriazol-1 -yloxy-tris(dlmethylamino)phosphonium hexaBuorophosphate (1.17 g, 2.64 mmoi) and the mixture was stirred for 16 hours under a nitrogen atmosphere. The mixture was diluted with 25 mL of 1 N hydrochloric 20 add and 25 mL of ethyl acetate. The organic layer was removed and the aqueous layer was extracted with ethyl acetate (2 x). The combined organic layers were washed with saturated aqueous sodium carbonate (1 x) and brine (1 x). The organic layer was dried (sodium sulfate), filtered, and the filtrate was concentrated in vacuo. Purification of the viscous yellow residue by flash chromatography (eiuting with 1:1 ethyl acetate/hexanes) 25 gave 810 mg of (2B,4R)-2-benzyloxycarbamoyl-1 -{3-(4-fluorophenoxy)-propane-1 -sulfonylJ-piperidine-4-carboxylic add methyl ester as a dear oil. <br><br> (d) A mixture of (2£,4B}-2-benzyloxycart&gt;amoyl-1-[3-(4-fluorophenoxy)-propane-1-sutfonyl]-piperidine-4-carboxylic add methyl ester (800 mg, 1.57 mmoi) and 200 mg of 5% palladium on barium sulfate in 15 mL of methanol was shaken in a Parr apparatus <br><br> 30 under a 40 psi hydrogen gas atmosphere for 2 hours. The catalyst was removed by passage of the mixture through a 0.45 pm nylon filter and the filtrate was concentrated to give 650 mg of (2B,4R)-1-[3-(4-fluorophenoxy)-propane-1-sulfonylJ-2- <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -41- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -40- <br><br> hydroxycarbamoyl-plperidlne-4-carboxyHc acid methyl ester as a white foam: MS (atmospheric pressure chemical ionization) acidic mode, 417 (M-1); 'H NMR (400 MHz, CDCij) 6 6.94-6.97 (m, 2 fcj), 6.80-6.63 (m, 2 fcj), 4.56 (s, 1 H), 4.03 (t, 2 ft A - 5.3 Hz), 3.83 (d. 1 ft £ - 12.9 Hz), 3.68 (s, 3 KJ), 3.15-3.28 (m, 3 jj), 2.76 (t, 1 ft J » 11.5 Hz), 5 2.54 (d, 1 ft J = 13.5 Hz), 2.26 (d, 2 H. i = 5.9 Hz), 2.02 (m, 1H,J = 13.0 Hz), 1.73-1.78 (m, 1 H), 1.56-1.62 (m, 1 H). <br><br> ISfflPl* 3 <br><br> {2R.4RM-r3-/4-FluoroDh«noxvV-orooane-1-aulfonvlT-2-hvdroxvcarbamovl-ptoeridtne-4-carboxvUc acid <br><br> 10 To a stirred, cold (0 °C) solution of (2Q,4R)-1 -[3-(4-fluorophenoxy)-propane-1 - <br><br> sulfonyl]-2-hydroxycarbnmoyi-piperidin&amp;-4-carboxyiic acid methyl ester (400 mg, 0.96 mmoi) in 5 mL of a methanoi/Water mixture (10:1) was added lithium hydroxide monohydrate (120 mg, 2.88 mmoi). After 3 hours at 0 °C, prerinsed (methanol) Amberlite resin (4.1g) was added. The mixture was filtered and the filtrate was 15 concentrated to give 370 mg of (2B,4Q)-1-[3-(4-fiuorophenoxy)-propane-1-suffonyf]-2-hydroxycarbamoyi-pipeddin»-4-carboxylic acid as a white foam: MS (atmospheric pressure chemical ionization) acidic mode, 403 (M-1). <br><br> ftqtmpl* 4 <br><br> (2R.4RWl-r4-f4-Fluorobenzvtoxvl-benzene8ulfonvfl-2-hvdroxvcarbamovl« 20 oloeridlne-4-carboxvllc acid methvl ester <br><br> 4-(4-Fluoro-benzyioxy)-benzen«sutfonyi chloride. MS: 465 (M-1). <br><br> The titled compound of example 4 was prepared by a method analogous to that described in example 2 using the reagents. <br><br> Smmplt 5 <br><br> 25 (2R.4RV-1-f4-/4-Fluorobanzyloxv&gt;-benzeneauHonvl'l-2-hvdroxvcarbamovl- <br><br> p|peridlne-4-carboxvllc acid. MS: 451 (M-1). <br><br> The titled compound of example 5 was prepared by a method analogous to that described in example 3 starting with 1-[4-(4-Ruoro-benzyloxy)-benzenesuifbnyi]-2-hydroxycarbamoyi-piperidlne-4-carboxyiic acid methyl ester. <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -42- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -41- <br><br> Exampl* e <br><br> 2R.3S-/1-f4»/4-nuorobenzvloxvy-benzenemjlfonvll-2-hvdroxvcarbamovt-alparidtn-3-wlV-carbamte add laopropvl ester <br><br> (a) To a stirred, cold (0 °C) solution of the known (Agami, C.; Harnon, L; <br><br> 5 Kadouri-Puchot, C.; Le Guen, V J. Org. Chem. 1996, §1, 5736-5742) [4§-4a,9ar,9aar]-1 -oxo-4-phenyl-octahydro-pyrido[2,1 -£][1,4]oxazin»-9-carboxyllc acid methyl ester (8.2B g, 2.86 mmoi) in 100 mL of tetrahydrofuran was added 2.39 mL of concentrated hydrochloric acid. After 5 minutes the mixture was concentrated to dryness. The resulting solid was suspended in ethyl acetate and the mixture was 10 stirred for an hour. The solids were collected by filtration, rinsed with ethyl acetate, and dried to give 9.04 g of a white solid. <br><br> Two grams of this solid was dissolved in 26 mL of 6 N hydrochloric acid and heated at reflux for 6 hours. The mixture was cooled to 0 °C and neutralized with 3 N sodium hydroxide and concentrated in vacuo. The resulting solids were 15 suspended in chloroform and passed through a 45 jum nylon filter. The filtrate was concentrated to a yellow oil which was purified by flash chromatography (etuting with 2:1 hexanes/ethyl acetate with 1% acetic acid) to give 802 mg of [4S-4a,9a,9aaf]1-oxo-4-phenyi-octahydro-pyi1do[2,1-s][1,4]oxazine-9-carboxyiic acid as white solid. <br><br> 20 (b) To a stirred solution of [4§-40,9a,9aa]1-oxo-4-phenyi-octahydro- <br><br> pyrido[2,1-£][1,4]oxazine-9-carboxylic add (568 mg, 2.06 mmoi) in 15 mL of benzene was added triethylamine (0.28 mL, 2.06 mmoi) and diphenyiphosphoryl azide (0.44 mL, 2.06 mmoi) at 22 °C under a nitrogen atmosphere. The mixture was stirred at 22 °C for 45 minutes and at reflux for 50 minutes before 2-propanol (3.2 25 mL, 41.2 mmoi) was added. After an additional 20 hours at reflux the mixture was cooled to 22 °C and concentrated in vacuo. The residue was taken up in ethyl acetate and the resulting solution was washed with 5% citric add, water, saturated aqueous sodium bicarbonate, and brine. The organic layer was dried (sodium sulfate), filtered, and the filtrate was concentrated in vacuo. The yellow residue was 30 purified by flash chromatrography (eluting with 3:1 hexanes/ethyl acetate) to give 402 mg of (4§-4cr,9cr,9aar]{1 -oxo-4-phenyt-octahydro-pyrido[2,1 -£] [1,4]oxazin-9-yl)-carbamic add isopropy) ester as white solid. <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -43- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -42- <br><br> (c) A mixture of [4§-4o,9o,9ao](1 -oxo-4-phenyl-octahydro-pyrido[2,1 -c][1,4]oxazin-9-yl)-carbamic acid isopropyl ester (900 mg , 2.71 mmoi) and 20% palladium hydroxide on carbon (920 mg) in 77 mL of ethanol/water (10:1) was shaken in a Parr apparatus under a 45 psi hydrogen gas atmosphere for 72 hours. <br><br> 5 The catalyst was removed by passage of the mixture through a 0.45 /jm nylon filter and the filtrate was concentrated to give 610 mg of 2B.3S-3-isopropoxycart&gt;onyJamino-piperidine-2-carboxylic acid as white solid. MS: 229 (M-1). <br><br> (d) To a stirred solution of 2B,3§-3-Jsopropoxycarbonylamino-piperidine-2-carboxylic acid (320 mg, 1.39 mmoi) in 5 mL of methylene chloride was added <br><br> 10 triethylamine (0.58 ml_ 4.17 mmoi) followed by 4-(4-fluorobenzyloxy)- <br><br> benzenesulfonyl chloride (460 mg, 1.53 mmoi). After 16 hours at 22 °C the mixture was portioned between 1 N hydrochloric acid and ethyl acetate. The organic layer was removed and washed with brine and dried over sodium sulfate. Filtration and concentration of the filtrate gave 480 mg of crude 2B.3S-1 -[4-(4-fluorobenzyloxy)-15 benzenesuifonyl]-3-&lt;sopropoxycarbonyiamino-piperfdine-2-carboxytic add as a light yellow solid. <br><br> (e) To a stirred, cold (0 °C) solution of crude 2B,3§-1-[4-(4-ftuorobenzyloxy)-benzenesulfonyl]-3-i*opropoxycarbonyl amino-piperidine-2-carboxylic acid (380 mg, 0.77 mmoi) in 5 mL of methylene chloride was added <br><br> 20 triethylamine (0.32 mL, 2.31 mmoi) followed by benzotriazol-1 -yioxy- <br><br> tris(dimethyiamino)phosphonium hexafluorophosphate (510 mg, 1.15 mmoi). The resulting solution was stirred for 2 minutes at 0 °C under a nitrogen atmosphere before 0-(trimethy)sitylethyi)hydroxylamine hydrochloride (195 mg, 1.15 mmoi) was added. The mixture was allowed to warm slowly to 22 °C over 14 hours. The 25 mixture was concentrated in vacuo and the residue was diluted with water and extracted with ethyl acetate/diethyl ether (1:1; 3 x). The combined organic extracts were washed with saturated aqueous carbonate (2 x), water (2 x), and brine (1 x). The organic layer was dried (magnesium sulfate), filtered, and the filtrate was concentrated in vacuo. The yellow residue was purified by flash chromatography 30 (eluting with 65:35 hexanes/ethyl acetate) to give 300 mg of 2R,3S-[1-[4-(4- <br><br> fluorobenzyfoxy)-benzenesulfonyl]-2-(2-trimethyl8ilanyl-ethoxycarbamoyl)-piperidin-3-yf]-carbamic acid isopropyl ester as a white foam. MS: 610 (M+1). <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -44- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -43- <br><br> (f) To a stirred, cold (0 °C) solution of 2S,3S-[1 -(4-(4-fIuorobenzyfoxy)-benzenesulfonyl]-2-{2-trimethytsilanyi-«thoxycart3anioyl)-piperidin-3-yl]-cart&gt;amic acid isopropyl ester (265 mg, 0.44 mmoi) in 4 mL of methylene chloride was added 3 mL of trifluoroacetic acid. The resulting colorless solution was allowed to warm to 23 °C 5 over 2 hours and was stirred for an additional 28 hours. The mixture was concentrated in vacuo to a solid/foam, which was suspended in ethyl acetate hexanes (1:6) and stirred for 10 hours. The white solids were collected by filtration, rinsed with hexanes, and purified further by flash chromatography (eluting with 7:3 ethyl acetate/hexanes with 1% acetic acid) to give 130 mg of 2f3,3S-1-{4-(4-10 fluorobenzyloxy)benzenesulfony1]-2-hydroxycart&gt;amoyi-plperidin-3-yl}-carbainic add isopropyl ester as a white solid/foam. MS: 510 (M+1). <br><br> Example 7 <br><br> 3-($)-4-(4'-F1uofoblphenYl-4^ulfonYl)-2,2-dimethYi-thioniorphp|lne-3-c?rbpxyllc acid frYdroyyqmltfr <br><br> 15 (a) To a stirred solution of the known (PCT Publication WO 97/20824) 3- <br><br> (S)-dimethytthexytsilyl-2,2-d4methyl-tetrahydro-2tl-1,4-thiazine-3-carboxyiate (1.17 g, 3.70 mmoi) in 6 mL of methylene chloride was added triethylamine (1.02 mL, 7.40 mmoi) followed by 4-fluorobiphenyisulfonyl chloride (1.0 g, 3.70 mmoi). The resulting solution was stirred for 56 hours at 23 °C. The reaction mixture was diluted 20 with methylene chloride and washed with water. The organic layer was concentrated in vacuo; the residue was dissolved in methanol, and the mixture was heated at reflux for 6 hours. The mixture was cooled to 23 °C and concentrated in vacuo. The residue was purified by flash chromatography (eluting with 3:7 ethyl acetate/hexanes with 0.1% acetic acid) to give 670 mg of 3-(§)-4-(4'-fluorobiphenyl-4-sulfonyl)-2^2-25 dimethyMhiomorpholine-3-carboxylic acid as a white foam/solid. MS: 427 (M+NH4). <br><br> (b) To a stirred, cold (0 °C) solution of 3-(S)-4-(4'-fluorobiphenyl-4-suifonyl)-2,2-dimethyWhiomorpholine-3-carboxylic acid (605 mg, 1.48 mmoi) in 5 mL of methylene chloride was added triethylamine (0.62 mL, 4.43 mmoi) under a nitrogen atmosphere. Benzotriazol-1 •y(oxy-tris(dimethytamino)phosphonium 30 hexafluorophosphate (980 mg, 2.22 mmoi) was added and the resulting solution was stirred for 5 minutes before 2-(trimethyisilyiethyi)hydroxylamine hydrochloride (376 mg, 2.22 mmoi) was added. The Ice bath was removed and the mixture was <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -45 <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -44- <br><br> stirred for 20 hours at 23 °C. The mixture was diluted with aqueous ammonium chloride and extracted with 1:1 ethyl acetate/dlethyi ether (3 x). The combined organic extracts were washed with saturated aqueous sodium carbonate (2 x), water (1 x), and brine (1 x). The organic layer was dried (magnesium sulfate), filtered, and 5 the filtrate was concentrated in vacuo. The residual yellow oil was purified by Hash chromatography (eluting with 3:7 ethyl acetate/hexanes) to give 660 mg of 3-{S)-4-(4'-fluorobiphenyl-4-sulfonyl}-2,2-dimethyMhiomorphollne-3-carboxyiic acid (2-trimethylsiianyi-ethoxy)-amide as a white foam. MS: 523 (M-1). <br><br> (c) A solution of 3-(§)-4-(4'-fiuorobiphenyi-4-sulfonyl)-2,2-dimethyl-10 thiomorpholine-3-carboxyiic add (2-trimethylsilanyt-ethoxy)-amide (650 mg, 1.24 mmoi) in 8 mL of trifluoroacetic add was stirred for at 22 °C for 16 hours. The mixture was concentrated in vacuo and the residue was triturated with methylene chloride and diethyl ether. The solvent was removed to give 550 mg of a tan solid. The solid was suspended in 1:1 diethyl ether/hexanes and stirred gently for 20 15 hours. The solids were collected by filtration (1:1 diethyl ether/hexanes rinsing) and dried to give 470 mg of 3-(§)-4-(4'-fluorobiphenyl-4-eulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide as white solid. MS: 423 (M-1). <br><br> ftmrrnh f <br><br> 3-(S)-4-r4-/4-Fiuorobenrvloxv)bsnzene»ulfonvn-2.2-dlmethvl-20 thiomomhoHne-3 -carboxvllc acid hvdroxvamlde <br><br> (a) To a stirred, cold (0 °C) solution of the known (Belgian Patent Publication BE 893025) 2,2-dimethyt-thiomorphoiine*3-carboxylic acid (600 mg, 3.42 mmoi) in 10 mL of 1:1 water/dioxane was added 6 N sodium hydroxide (1.2 mL, 7.1 mmoi). To the resulting solution 4-(4-fluorobenzyioxy)benzenesulfonyi chloride (1.08 25 g, 3.77 mmoi) was added. After 30 and 60 minutes an additional 1 gram of 4-(4-fluorobenzyioxy)benzeneeuifonyt chloride and 1.2 mL of 6 N sodium hydroxide was added. The mixture (pH ca. 12) was diluted with water and extracted with diethyl ether (1 x). The ethereal layer was washed with 1 N sodium hydroxide; the combined basic aqueous layers were acidified to pH 3 using concentrated 30 hydrochloric add, and the addic mixture was extracted with ethyl acetate (3 x). The combined organic extracts were dried (sodium sulfate), filtered, and the filtrate was concentrated in vacuo to give 820 mg of 3-(§)-4-[4-(4- <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -46- <br><br> V <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> -46- <br><br> fluorobenzyloxy)benzenesuHonyl]-2,2-dimethyi-thiomorpholine-3-carboxylic acid as a white solid. MS: 438 (M-1). <br><br> (b) To a stirred, odd (0 °C) solution of 3-(§)-4-[4-(4-fluorobenzytoxy)-benzenesuHonyi]-2,2-dimethyi-thiomorpholine-3-carboxylie add (820 mg, 1.87 mmoi) <br><br> 5 in 5 mL of methylene chloride was added triethylamine (0.52 mL, 3.74 mmoi) under a nitrogen atmosphere. Benzotriazol-1 -ytoxy-tHs(dim«thytamino)phosphonium hexafiuorophosphate (1.24 g, 2.81 mmoi) was added and the resulting solution was stirred for 5 minutes before O-rtert-butvidimethvtsilvilhvdroxvlamine (550 mg, 3.74 mmoi) was added .The ice bath was removed and the mixture was stirred for 16 10 hours at 23 °C. Hie mixture was diluted with aqueous ammonium chloride and extracted with ethyl acetate (3 x). The combined organic extracts were washed with water, brine, and dried over sodium sulfate. Filtration and concentration of the filtrate gave a viscous yellow oil, which was purified by flash chromatography (eluting with 1:3 ethyl acetate/hexanes) to give 270 mg of 3-(S)-4-{4-{4-15 fluorobenzyioxy)benzenesuffonyl]-2,2-dlmethyl-thlomorphollne-3-cart}oxylic acid ftert-butyidimethylsiloxy)-amide as a white foam. MS: 569 (M+1). <br><br> (c) To a stirred, cold (0 °C) solution of 3-(§)-4-[4-(4-fluorobenzyloxy)-benzenesulfonyl] -2,2-dimethyf-thiomorphoiine-3-carboxyiic acid ftert-butyidimethyisiioxy)-amide (270 mg, 0.47 mmoQ in 10 mL of tetrahydrofuran was <br><br> 20 added two drops of concentrated hydrochloric acid. After 30 minutes the mixture was diluted with 15 mL of tetrahydrofuran and the mixture was concentrated in vacuo to a volume of ca. 5 mL The volume was adjusted to ca. 25 mL with tetrahyrofuran and the mixture was concentrated again to ca. 5 mL This process was repeated twice more before the mixture was finally concentrated to dryness. 25 The resulting solids were suspended in a mixture of hexanes and diethyl ether and the mixture was stirred for 16 hours. The solid were collected by filtration, rinsed with diethyl ether,and dried to give 180 mg of 3-(§)-4-[4-{4- <br><br> fluorobenzytoxy)benzenesutfonyi]-2,2-dimethyMhiomorpholine-3 -carboxyiic add hydroxyamide as a white solid. MS: 453 (M-1). 'H NMR (400 MHz, dmso-d^ 6 10.63 30 (s, 1 tfl, 8.80 (bs, 1 fcD 7.59-7.61 (m, 2 jj), 7.46-7.50 (m, 2 fci), 7.17-7.21 (m, 2 H). 7.09-7.12 (m, 2 fcD, 5.12 (s, 2 fcD, 3.99 (s, 1 fcD, 3.87-3.93 (m, 1 fcD. 3.69 (d, 1 H. J = 12.7 Hz). 2.78-2.86 (m, 1 fci), 2.44-2.50 (m, 1 H), 1.35 (s, 3 JH), 1.12 (s, 3fcfi. <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -47- <br><br> WO 98/34918 <br><br> PCT/IB98/00064 <br><br> •46- <br><br> Praparatlon 1 4-f4»FluorobenzvtoxvM&gt;enzeneauHonvi chloride <br><br> To a stirred solution of 4-hydroxybenzenesuifonic add sodium salt dihydrate (5.13 g, 22.1 mmoi) in 23 mL of 1 N sodium hydroxide was addad a solution of 4-5 fluorobenzyt bromide (3.3 mL, 26.5 mmoi) in 20 mL of ethanol. The mixture was heated at reflux for two days, then cooled to ambient temperature (22 °C), whereupon a white precipitate formed. The flaky white solids were collected by filtration, rinsed with ethyt acetate and diethyl ether, and dried to give 4. 95 g of 4-(4-fluoro-benzyioxy)-benzenesuifonic add sodium salt. A stirred solution of 4-{4-fluoro-10 benzyioxy)-benzenesulfonic add sodium salt (13.0 g, 42.7 mmoi) in 50 mL of thionyi chloride and two drops of dimethyiformamide was heated at a gentle reflux for 8 hours. The mixture was concentrated to a yellow solid which was suspended in ethyl acetate and filtered. The filtrate was concentrated to 11.2 g of 4-(4-fluorobenzyioxy)benzenesutfonyi chloride as a light yellow solid: 'H NMR (400 MHz, 15 CDCIj) 5 7.95-7.98 (m, 2 H), 7.38-7.41 (m, 2 fcD, 7.08-7.12 (m, 4 H), 5.12 (s, 2 fcj). <br><br> Prwwnttan Z <br><br> 3-(4-FiuorophenoxvV-oropane-1 -sulfonvi chloride <br><br> To a stirred solution of 4-fluorophenol (5.0 g, 44.6 mmoi) in 50 mL of toluene was added sodium hydride (60% dispersion in mineral oil, 1.78 g, 44.6 mmoi) at 20 ambient temperature (22 °C). After 20 minutes, a solution of 1,3-propane sutfone (3.9 mL, 44.6 mmoi) in toluene was added slowly and the mixture was stirred for 16 hours. The reartion was quenched by the addition of methanol and the mixture was concentrated in vacuo to an off-white solid. This solid was suspended in ethyl acetate, filtered, and the solids were collected and dried to give 10.9 g of 3-{4-25 fiuorophenoxy)-propane-1 -sulfonic acid sodium salt as an off-white powder. A stirred solution of 3-{4-fluorophenoxy)-propane-1 -sulfonic add sodium salt (2.0 g, 7.8 mmoi) in 10 mL of thionyi chloride and one drops of dimethyiformamide was heated at reflux for 16 hours. The mixture was then cooled to 0 °C, diluted with 25 mL of diethyl ether, and Vie reaction was quenched by the slow addition of water. The 30 organic layer was removed and the aqueous layer was extracted with 25 mL of diethyl ether. The combined organic layers were washed with brine and dried over <br><br> Printed from Mimosa 07/26/1999 10:15:38 page -48- <br><br> WO 98/34918 <br><br> PCT/IJJ98/00064 <br><br> -47- <br><br> sodium sulfate. Filtration and concentration gave 1.75 g of 3-(4-fluoro-phenoxy)-propane-1-suifonyl chloride as a yellow oil: 1H NMR (400 MHz, CDCI,) 6 6.96-7.00 (m, 2 H), 6.80-6.84 (m, 2 H), 4.10 (t, 2 H, J = 5.5 Hz), 3.91 (t, 2 M, J - 7.5 Hz) 2.47-2.54 (m, 2 tD- <br><br> 5 Preparation 3 <br><br> 4'-Fluorobluhenvlsulfonvt chloride <br><br> Chlorosulfonic acid (8.7 mL, 0.13 mole) was added dropwise to stirred cold (0 °C) 4-fluoroblphenyl (10.2 g, 59 mmoi). After 30 minutes at 0 °C the reaction mixture was poured onto ice. The resulting white precipitate was collected by 10 filtration and dissolved in chloroform. The chloroform solution was washed with water, brine, dried over magnesium sulfate, and concentrated to afford a white solid. The desired 4Mluorobiphenyisuifonyl chloride (4.3 g), was separated from 4'* fluorobiphenylsutfonic acid by crystallization of the latter from ethyl acetate and crystallization of the remaining material from hexanes. <br><br> Printed from Mimosa 07/26/1999 <br><br> 10:15:38 page -49- <br><br></p> </div>

Claims (4)

<div class="application article clearfix printTableText" id="claims"> <p lang="en"> -48-<br><br> WHAT WE CLAIM IS:<br><br> 1 • A compound of the formula<br><br> R5 R6<br><br> 33 6836<br><br> R4 \ / R8<br><br> \ \* i<br><br> R<br><br> I<br><br> ■OH<br><br> R2 S02<br><br> H<br><br> Q<br><br> or the pharmaceuticaily acceptable salt thereof, wherein the broken line represents an optional double bond;<br><br> X is carbon;<br><br> Y is carbon;<br><br> R\ R2, R3, R4, R5, R8, R7, R8 and R9 are selected from the group consisting of hydrogen, hydroxy, (C1-Ca)alkyl optionally substituted by one or two groups selected from (Q-C6)alkylthio, (CrQOalkoxy, trifluoromethyl, halo, (Q-C10)aryl, (C2-C9)heteroaryl, (Ce-C10)arylamino, (Ce-C^arylthio, (CVC^aryloxy, (C2-C9)heteroarylamino, (Cj-CgJheteroarylthio, (C2-C9)heteroaryloxy, (Ce-C^JaryKCe-C^Jaryl, (C3-C6)cycloalkyl, hydroxy, piperazinyl, (Q,-CioJaryKCrCeJalkoxy, (Cj-QOheteroaryKCVCsJalkoxy, (C^CsJacylamino, (Q-CeJacylthio, (C,-C6)acyloxy, (CVCeJalkylsulfinyl, (C6-C10)arylsulfinyl, (Q-CeJalkylsulfonyl, (Ce-C10)aryisulfonyl, amino, (C,-C6)alkylamino or ((G1*C6)alkyl)2amino; (C2-C6)aikenyl, (Ca-C10)aryl(C2-CB)alkenyl, (C2-C9)heteroaryl(C2-Ce)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl(C2-C6)alkynyl, (Qj-C^heteroaryKCr C6)alkynyl, (CVCeJalkylamino, (CrCgJalkylthio, (CVCeJalkoxy, perfluoro(C1-C8)alkyl, (Ce-C10)aryl, (Cz-C9)heteroaryl, (C6-C10)arylamino, (C6-C10)arylthio, (C6-C10)aryloxy, (C2-C9)heteroarylamino, (C2-C9)heteroarylthio, (C2-C9)heteroaryloxy, (C3-C6)cycloalkyl, (CVC^alkyKhydroxymethylene), piperidyl, (CVCaJalkylpiperidyl, (CrC6)acylamino, (C1-C6)acylthio, (Q-C^acyloxy, R10^-C6)alkyl or a group of the formula<br><br> INTELlBQTUAL PROPERTY OFFICE OF N.Z.<br><br> 1 h JUL 2000<br><br> RECEIVED<br><br> &lt;u&gt;.<br><br> IE<br><br> &lt;CH2)n ^ ■&gt;<br><br> wherein n is 0 to 6;<br><br> yisOor 1;<br><br> W is oxygen or &gt;NR24;<br><br> Z is -OR11, -NR24R11, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl or a bridged diazabicycloalkyl ring selected from the group consisting of<br><br> &lt;ch2&gt;„<br><br> v 2&gt;<br><br> TT<br><br> CCH2)r<br><br> &lt;CH2)P<br><br> wherein r is 1,2 or 3; mis 1 or 2;<br><br> pisOor 1; and<br><br> &lt;CHg),<br><br> INTELLECTUAL PROPERTY OFFICE OF N.Z.<br><br> 1 4 jul 2000 RECEIVED<br><br> -50-<br><br> ^ '? .■/ •: " -J &lt;rp cv \j<br><br> V is hydrogen, &lt;Ot-C3)alkyl&gt; (CrC6)alkyl(C=0)-, (CrC6) alkoxy(C=0)-, (Qj-Cio)aryl(C=0)-, (C6-C10)aryloxy(C=O)-, (C6-Cio)aryl(Ci-C6)alkyl(C=0)-, (C8-Cio)aryl-(Ci-C6)alkoxy(C=0)-, or (C1-C6)alkoxy(C=P)-0-;<br><br> wherein each heterocyclic group may optionally be independently substituted by one or two groups selected from hydroxy, (C,-C6)alkyl, (C1-C6)alkoxy, (CrC^acyl, (C^C^Jacyloxy, (C6-C10)aryl, (C2-C9)heteroaryl, (Cs-C^aryKCVCeJalkyl, (Cz-CgJheteroaryKCrCgJalkyl, hydroxyCCrCeJalkyl, (CVCJalkoxytCfC^alkyl, (C1-C6)acyloxy(C1-C6)alkyl, (Q-CeJalkylthio, (C,-C6)alkylthio(CrC6)alkyl, (C6-C10)arylthio, (CVCJarylthiofCrCeJalkyI, R12R13N-, R12R13NS02-, R12R13N(C=0)-, R12R13N(C=0)-(C1-C6)alkyl, R14SOz-, R14S02NH-, R15(C=0)-[N(R12)]-, R160(C=0K or R160(C=0HCrCe)alkyl;<br><br> wherein R10 is (C^CeJacylpiperazinyl, (C6-C10)arylpiperazinyl, (Q&gt;-C9)heteroarylpiperazinyl, (CrC6)alkylpiperazinyl, (C6-C10)aryl(C1-C8)alkylpiperazinyl, (C2-CgJheteroaryKC^CeJalkylpiperazinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidyl, (C,-C6)alkylpiperidyl, (Ce-C10)arylpiperidyl, (C2-C9)heteroarylpiperidyl, (Q-CeJalkylpiperidyKC,-C6)alkyl, (Ce-C^JarylpiperidyKCrCeJalkyl, (C2-Ce)heteroaryl-piperidyl-(C1-C6)alkyl or (Cr Cs)acylpiperidyl;<br><br> R11 is hydrogen, (C6-C10)aryl, (Cj-CgJheteroaryl, (Qs-C^aryKCVCeJalkyl, (C2-C9)heteroaryl(C,-C6)alkyl, (CrCeJalkyKCe-C^aryKCVCeJalkyl, (C^CeJalkyKCj-CgJheteroaryKCr C8)alkyl, 5-indanyl, -CHR170-(C=0)-R18 or -CH2(C=0)-NR19R20;<br><br> R12 and R13 are each independently hydrogen, (C,-Ce)alkylf (Ce-C10)aryl, (Cj-C9)heteroaryl, (Ce-C^JaryKC^CeJalkyl or (Cz-CgJheteroaryKC^CgJalkyl or R12 and R13 may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or thiomorpholinyl ring;<br><br> R14 is trifluoromethyl, (C,-C8)alkyl, (CB-C10)aryl, (CVC^heteroaryl, (QrCio)ary'(Cr C6)alkyl or (CVCe)heteroaryt(C1-C6)alkyl;<br><br> R15 is hydrogen, (C,-C6)alkyl, (CrC6)alkoxy, (C8-C10)aryl, (Cj-CgJheteroaryl, (Cr Ce)aryl(C1-C6)alkyl(C6-C10)aryl(C1-C8)alkoxy or (C2-Cfl)heteroaryl(C1-C8)alkyl;<br><br> R16 is (CrCeJalkyl, (Ce-C10)aryl, ((VC9)heteroaryl, (Co-C^aryKCrCaJalkyl, 5-indanyl, -[CH(R17)]0-(C=0)-R18,-CH2(C=0)-NR19R20, orR210(C1-C8)alkyl;<br><br> R17 is hydrogen or (C^CaJalkyl;<br><br> R18 is (C^CeJalkyl, (CrC8)alkoxy or (C8-C10)aryl;<br><br> R19 and R20 are each independently hydrogen or (CVC6)alkyl or may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl,<br><br> morpholinyl or thiomophoiinyl ring; -<br><br> a i intellectual property office of n.z.<br><br> iv jul 2000 RECEIVED<br><br> -51 -<br><br> R21 is H2N(CHR22)(C=0)-;<br><br> R22 is the side chain of a natural D- or L-amino acid;<br><br> R23 is hydrogen, (CrC6)acyl, (C^-CaJalkyl, (C6-C10)aryl(C1-C6)aikyl, (C2-C9)heteroaryl(Cr C6)alkyl or (CVCeJalkylsulfonyl;<br><br> R24 wherever it occurs is independently hydrogen or (C,-C6)alkyl;<br><br> or R1 and R2, or R3 and R4, or R5 and R6 may be taken together to form a carbonyl; or R1 and R2, or R3 and R4, or R5 and R6, or R7 and R8 may be taken together to form a (C3-C6)cycloalkyl, oxacyclohexyl, thiocyclohexyl, indanyl or tetralinyl ring or a group of the<br><br> Q is (Ce-C1o)aryl(Cs-C10)aryl, (C6-C10)aryl(C1-C6)alkoxy(Ca-C10)aryl or (C,-C9)heteroaryl(C1-C6)alkoxy(C6-C10)aryl optionally substituted by fluoro, chloro, (C,-C,)alkyi, (C.,-C8)alkoxy or perfluoro(C.,-C3)alkyl;<br><br> with the proviso that when R1, R2, R3, R4, R5, R6, R7, R®, and R9 are all defined by hydrogen or (C.,-C6)alkyl, the broken line represents a double bond;<br><br> with the proviso that when R1, R2 and R9 are a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 2- or 6- positions of the ring;<br><br> with the proviso that when y is 1 and W is NFP4 or oxygen, Z cannot be hydroxy;<br><br> with the proviso that when the broken line represents a double bond, Pf and R6 are not present;<br><br> with the proviso that when R? and R5 are independently a substituent comprising a heteroatom when the broken line represents a double bond, the heteroatom cannot be directly bonded to positions X and Y.<br><br> formula<br><br> R23<br><br> INltLLEQTUAL PHOPERTY OFFICE OF N.Z.<br><br> 1 4 jul 2000 RECEIVED<br><br> -52-<br><br> A compound of the formula<br><br> &gt;56836<br><br> R4 \ / Ra f. \ ^ ^<br><br> R5 R6<br><br> R2 S02<br><br> H<br><br> •OH<br><br> I<br><br> Q<br><br> or the pharmaceuticaily acceptable salt thereof, wherein the broken line represents an optional double bond;<br><br> X is carbon;<br><br> Y is carbon;<br><br> R\ R2, R3, R\ R5, R8, R7, R8 and R9 are selected from the group consisting of hydrogen, hydroxy, (CrC6)alkyl optionally substituted by one or two groups selected from (Cj-Ce)alkylthio, (Ci-C^alkoxy, trifluoromethyl, halo, (Q-C10)aryl, (Cj-CgJheteroaryl, (C#-C10)arylamino, (C8-C10)arylthio, (C6-C10)aryloxy, (Cj-C^heteroarylamino, (Cj-CgJheteroarylthio, (C2-C9)heteroaryloxy, (C6-C10)aryl(C8-C10)aryl, (C3-C8)cycloalkyl, hydroxy, piperazinyl, (Q,-Ci0)aryl(C1-C8)alkoxy, (Cz-CgJheteroaryKQ-C^lkoxy, (Ci-C^acylamino, (C,-Ce)acylthio, (C,-C6)acyloxy, (CVC^alkylsulfinyl, (C8-C10)arylsulfinyl, (CVQOalkylsulfonyl, (Ca-C^arylsulfonyl, amino, (CrC8)alkylamino or ((CVC^alkylJaamino; (C^-G8)alkenyli (C8-G10)aryl(C2-G8)alkenyl, (C2-C9)heteroaryl(C2-C8)alkenyl, (Cj-CeJalkynyl, (Ce-C10)aryl(C2-C8)alkynyl, (Cg-C^heteroaryKQr C8)alkynyl, (C1-Ce)alkylamino, (CrC6)alkylthio, (CVC^alkoxy, perfluoro^-CeJalkyl, (C8-C10)aryl, (C2-C9)heteroaryl, (C8-C10)arylamino, (Ca-C10)arylthio, (CB-C10)aryloxy, (C2-C9)heteroarylamino, (C2-C9)heteroarylthio, (Cj-CgJheteroaryloxy, (C3-C6)cycloalkyl, (Q-C^alkyKhydroxymethylene), piperidyl, (CrC6)alkylpiperidyl, (CrC8)acylamino, (Q-CeJacylthio, (C^CeJacyloxy, R10^,-C6)alkyl or a group of the formula<br><br> INTELLECTUAL PROPERTY OFFICE OF NZ<br><br> 11 jul 2000<br><br> RECEIVED<br><br> -53-<br><br> &lt;H)y 11 &lt;cho).<br><br> !<br><br> wherein n is 0 to 6;<br><br> yisOor 1;<br><br> W is oxygen or &gt;NRZ4;<br><br> 2 is -OR11, -NR24R11, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl or a bridged diazabicycloalkyl ring selected from the group consisting of<br><br> &lt;CHa&gt;m<br><br> &lt;CH2&gt;ra<br><br> &lt;CH2&gt;r<br><br> "N<br><br> (ch2)p wherein r is 1,2 or 3; m is 1 or 2;<br><br> p is 0 or 1; and<br><br> INTELLECTUAL PROPERTY OFFICE OF N.Z<br><br> 1 h JUL 2000<br><br> RECEIVED<br><br> -54-<br><br> 33<br><br> V is hydrogen, (C^-Cgjalkyl, (C1-C6)alkyl(C=0)-, (C^Ce) alkoxy(C=0)-, (Q-Cio)aryl(C=0)-, (C8-C-)o)aryloxy(C=0)-, (C8-Cio)aryl(Ci-C8)alkyl(C=0)-, (Cg-CiQ)aryl-(Ci-C6)alkoxy(C=0)-, or (CrC6)alkoxy(C=0)-0-;<br><br> wherein each heterocyclic group may optionally be independently substituted by one or two groups selected from hydroxy, (C,-C6)alkyl, (C1-C6)alkoxy, (CrC^Jacyl, (C1-C10)acyloxy, (C6-C10)aryl, (C2-Cg)heteroaryl, (C6-C10)aryl(C1-C6)aikyl, (C2-C9)heteroaryl(C1-C6)alkyl, hydroxy(CrCe)alkyl, (C1-C6)alkoxy(C1-C6)alkyl, (C,-C6)acyloxy(C1-C6)alkyl, (CrC6)alkylthio, (C,-C6)alkylthio(CrC6)alkyl, (Ce-C^Jarylthio, (CB-CJarylthiofCVCeJalkyl, R12R13N-, R12R13NSOr, R12R13N(C=0)-, R12R13N(C=0)-(C1-C6)alkyl, R14S02-, R14S02NH-, R15(C=0)-[N(R12)]-, R160(C=0)-, or R160(C=0)-(C1-C8)alkyl;<br><br> wherein R10 is (CVC^acylpiperazinyl, (C6-C10)arylpiperazinyl, (CV C9)heteroarylpiperazinyl, (C1-C6)alkylpiperazinyl, (Ce-C^JaryKCrCeJalkylpiperazinyl, (Q,-CaJheteroaryKCrCeJalkylpiperazinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidyl, (Q-C6)alkylpiperidyl, (C8-C10)arylpiperidyl, (Cj-C^heteroarylpiperidyl, (CrC^alkylpiperidyKCr C6)alkyl, (C8-C10)arylpiperidyl(C1-C8)alkyl&gt; (C2-C9)heteroaryl-piperidyl-(C1-C8)alkyl or (C,-C8)acylpiperidyl;<br><br> R11 is hydrogen, (Ce-C^Jaryl, (C2-C9)heteroaryl, (QrCJaryKCrCeJalkyl, (Cj-C^JheteroaryKCrCaJalkyl, (Ci-C^alkyKCe-C^aryKCVCeJalkyl, (C1-C8)alkyl(C2-C9)heteroaryl(C1-C6)alkyl, 5-indanyl, -CHR170-(C=0)-R18 or -CH2(C=0)-NR19R20;<br><br> R12 and R13 are each independently hydrogen, (C,-C8)alkyl, (Ce-C10)aryl, (C^ C9)heteroaryl, (C^-C^JaryKCrCBjalkyl or (C2-C9)heteroaryl(C1-C6)alkyl or R12 and R13 may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or thiomorpholinyl ring;<br><br> R14 is trifluoromethyl, (C,-C8)alkyl, (C6-C10)aryl, (C2-C9)heteroaryl, (CB-C10)aryl(Cr C8)alkyl or (CVCgJheteroaryKGrCeJalkyl;<br><br> R1S is hydrogen, ((VCaJalkyI, (Q-CeJalkoxy, (Ca-C10)aryl, (C2-C9)heteroaryl, (Cr C6)aryl(C1-C6)alkyl(C8-C1o)aryl(C1-C8)alkoxy or (C2-C9)heteroaryl(C1-C6)alkyl;<br><br> R16 is (CrCeJalkyl, (C8-C10)aryl, (Qj-GoJheteroaryl, (Ca-C^JaryKCrCeJalkyl, 5-indanyl, -[CH(R17)]0-(C=0)-R18, -CH2(C=0)-NR19R20, or R210(C1-CB)alkyl;<br><br> R17 is hydrogen or (Q-C^alkyl;<br><br> R18 is (C1-Ce)alkyl, (C1-C8)alkoxy or (Ce-C10)aryl;<br><br> R19 and R20 are each independently hydrogen or (C,-C6)alkyl or may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl,<br><br> morpholinyl or thiomopholinyl ring;<br><br> INTELLECTUAL PROPERTY OFFICE OF N.Z.<br><br> 1 ^ jul 2000<br><br> RECEIVED<br><br> -55-<br><br> R21 is H2N (CH R22)(C=0)-;<br><br> R22 is the side chain of a natural D- or L-amino acid;<br><br> R23 is hydrogen, (C,-C6)acyl, (CVC^alkyl, (C6-C10)aryl(C1-C6)alkyl, (C2-C9)heteroaryl(Cr C6)alkyl or (CrCeJalkylsulfonyl;<br><br> R24 wherever it occurs is independently hydrogen or (C,-C6)alkyl;<br><br> or R1 and R2, or R3 and R4, or R5 and R6 may be taken together to form a carbonyl; or R1 and R2, or R3 and R4, or R5 and R6, or R7 and R8 may be taken together to form a (C3-C6)cycloalkyl, oxacyclohexyl, thiocyclohexyl, indanyl or tetralinyl ring or a group of the<br><br> Q is (C6-C10)aryl(C8-C10)aryl, (C8-C10)aryl(C1-C8)alkoxy(C8-C10)aryl or (C.,-C9)heteroaryl(C1-C6)alkoxy(Ce-C1o)aryi optionally substituted by fluoro, chloro, (C,-Cs)aikyl, (C^CgJalkoxy or perfluoro(C1-C3)alkyl;<br><br> with the proviso that when R1, R2, R3, R4, R5, R8, R7, R8, and R8 are all defined by hydrogen or (C1-Ce)alkyl, the broken line represents a double bond;<br><br> with the proviso that R7 is other than hydrogen only when R8 is other than hydrogen;<br><br> with the proviso that R8 is other than hydrogen only when R5 is other than hydrogen;<br><br> with the proviso thatR3 is other than hydrogen only when R4 is other than hydrogen;<br><br> with the proviso that R2 is other than hydrogen only when R1 is other than hydrogen;<br><br> with the proviso that when R1, R2 and R9 are a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 2- or 6- positions of the ring;<br><br> with the proviso that when y is 1 and W is NR24 or oxygen, Z cannot be hydroxy;<br><br> with the proviso that when the broken line represents a double bond, R4 and R6 are not present;<br><br> with the proviso that when R3 and R5 are independently a substituent comprising a heteroatom when the broken line represents a double bond, the heteroatom cannot be directly bonded to positions X and Y.<br><br> formula<br><br> R23<br><br> intellectual property office of n.z.<br><br> 1 * jul 2000<br><br> RECEIVED<br><br> 3. A compound of the formula<br><br> R4 \ / R8<br><br> r5 r6<br><br> R2 s02<br><br> H<br><br> •OH<br><br> I<br><br> Q<br><br> or the pharmaceuticaily acceptable salt thereof, wherein the broken line represents an optional double bond;<br><br> X is carbon;<br><br> Y is carbon;<br><br> R\ R2, R3, R4, R5, R6, R7, R8 and R9 are selected from the group consisting of hydrogen, hydroxy, (C.,-C6)alkyl optionally substituted by one or two groups selected from (Q-C6)alkylthio, (Q-CaJalkoxy, trifluoromethyl, halo, (Q-C10)aryl, (C2-C9)heteroaryl, (0,-C10)arylamino, (C8-C10)arylthio, (C6-C10)aryloxy, (C2-C9)heteroarylamino, (C2-C9)heteroarylthio, (CVQOheteroaryloxy, (C6-C1o)aryl(Ca-C10)aryl, (C3-C8)cycloalkyl, hydroxy, piperazinyl, (Q,-CioJaryKC^eJalkoxy, (C2-C9)heteroaryl(C1rC6)alkoxy, (CrCeJacylamino. (CVC^acylthio, (Cr C6)acyloxy, (C^CeJalkylsulfinyl, (Ca-C10)arylsulfinyl, (CVCeJalkylsulfonyl, (C9-C10)arylsulfonyl, amino, (CrGeJalkylamino or ((Ci-C6)alkyl)2amino; (C^-C6)alkenyl, (Ce-C10)aryl(C2-Cg)alkenyl, (C2-C9)heteroaryl(C2-C0)alkenyl, (Cg-CsJalkynyl, (C8-C10)aryl(C2-C6)alkynyl, (CrCgJheteroaryKCV C6)alkynyl, (CrCsJalkylamino, (CrCgJalkylthio, (C1-C6)alkoxy, perfluoro^-CsJalkyl, (Ce-C10)aryl, (C2-Cg)heteroaryl, (C8-C10)arylamino, (Ca-CioJarylthio, (C6-C10)aryloxy, (C2-C9)heteroarylamino, (C2-C9)heteroarylthio, (Cj-CgJheteroaryloxy, (C3-C8)cycloalkyI, ((VC^alkyKhydroxymethylene), piperidyl, (CVQOalkylpiperidyl, (CrC8)acylaminof (CVQOacylthio, (Ci-Cgjacyloxy, R10(Cr C6)alkyl or a group of the formula<br><br> INTELLECTUAL PROPERTY OFFICE OF N.Z.<br><br>
1 * jul 2000<br><br> RECEIVED<br><br> -57-<br><br> &lt;«&gt;„ 11<br><br> &lt;ch2)n wherein n is 0 to 6;<br><br> yisOorl;<br><br> W is oxygen or &gt;NR*4;<br><br> Z is -OR11, -NR24R11, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, indolinyl, isoindolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl or a bridged diazabicycloalkyl ring selected from the group consisting of<br><br> &lt;ch2)m<br><br> &lt;CHE&gt;m<br><br> V<br><br> cch2&gt;r y<br><br> N<br><br> &lt;CH<br><br>
2&gt;r<br><br> &lt;ch2)p wherein r is 1,2 or 3; m is 1 or 2; pis0or1;and<br><br> INTELLECTUAL PROPERTY OFFICE OF N.Z.<br><br> 1 * jul 2000<br><br> RECEIVED<br><br> ""T~? c-j<br><br> ■\ £ O<br><br> - 58 - vy ^ W [T<br><br> V is hydrogen, (Ct^alkyl, (C1-C6)alkyl(C=0)-, (Q-Cg) alkoxy(C=0)-, (Cg-Cio)aryl(C=0)-, (Cg-Cio)aryloxy(C=0)-, (Cg-Cio)aryl(Ci-Cg)alkyl(C=0)-, (Ce-Cio)aryl-(Ci-C6)alkoxy(C=0)-, or (C,-C6)alkoxy(C=0)-0-;<br><br> wherein each heterocyclic group may optionally be independently substituted by one or two groups selected from hydroxy, (Q-Cgjalkyl, (CVQOalkoxy, (CrCmJacyl, (C^C^Jacyloxy, (Cg-C10)aryl, (C2-C9)heteroaryl, (Cg-C^aryKCVC^alkyl, (Cz-C^heteroaryKCrCgJalkyl, hydroxyCCrCgJalkyl, (C1-C6)alkoxy(C1-C6)alkyl, (C1-C6)acyloxy(C1-C6)alkyl, (C^CgJalkylthio, (Cr C6)alkylthio(CrC6)alkyl, (Cg-C10)arylthio, (C6-C10)arylthio(C1-C6)alkyl, R12R13N-, R12R13NS02-, R12R13N(C=0)-, R12R13N(C=OHC1-Cg)alkyl, R14SOr, R14S02NH-, R15(C=0)-[N(R12)]-, R160(C=0)-, or R180(C=0)-(C1-C6)alkyl;<br><br> wherein R10 is (CrC6)acylpiperazinyl, (C8-C10)arylpiperazinyl, (C2-C9)heteroarylpiperazinyl, (CrCg)alkylpiperazinyl, (C6-C10)aryl(C1-C6)alkylpiperazinyl, (Q,-C9)heteroaryl(C1-C6)alkylpiperazinyl, morpholinyl, thiomorpholinyl, pyrrolidinyl, piperidyl, (Q-Ce)alkylpiperidyl, (C6-C10)arylpiperidyl, (C2-C9)heteroarylpiperidyl, (Q-CgJalkylpiperidyKC,-C8)alkyl, (Cg-C10)arylpiperidyl(C1-C6)alkyl, (Qz-CJheteroaryl-piperidyKCrCg^lkyl or (Cr C6)acylpiperidyl;<br><br> R11 is hydrogen, (CB-C10)aryl, (Ca-Cgjheteroaryl, (Cg-Cio)aryl(CrC6)alkyl, (Cr CaJheteroaryKCi-CgJalkyl, (C1-C6)alkyl(C6-C10)aryl(C1-Ce)alkyl, (C1-C6)alkyl(C2-C9)heteroaryl(C1-C6)alkyl, 5-indanyl, -CHR170-(C=0)-R18 or -CH2(C=0)-NR19R20;<br><br> R12 and R13 are each independently hydrogen, (C,-C6)alkyl, (Ce-C10)aryl, (Q&gt;-Cg)heteroaryl, (Cg-C1o)aryl(C1-Cg)alkyl or (C^-C^heteroaryKCrCeJalkyl or R12 and R13 may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or thiomorpholinyl ring;<br><br> R14 is trifluoromethyl, (C,-C6)alkyl, (C6-C10)aryl, (C2-C9)heteroaryl, (Cg-C^aryKCr C6)alkyl or (C2-G9)heteroaryl(C1-C6)alkyl;<br><br> R15 is hydrogen, (CrCg)alkyl, (C^CgJalkoxy, (Ce-C10)aryl, (C2-C9)heteroaryl, (Cr Cg)aryl(C1-C6)alkyl(Cg-C10)aryl(C1-C6)alkoxy or (Cg-CgJheteroaryKCrCoJalkyl;<br><br> R16 is (CrCgJalkyl, (Ce-C10)aryl, (C2-C9)heteroaryl, (Cg-C^JaryKC^gJalkyl, 5-indanyl, -[CH(R17)]0-(C=0)-R18, -CH2(C=O)-NR19R20i or R210(CrC8)alkyl;<br><br> R17 is hydrogen or (C^CgJalkyl;<br><br> R18 is (Q-CeJalkyl, (C^CgJalkoxy or (C8-C10)aryl;<br><br> R19 and R20 are each independently hydrogen or (C,-C6)alkyl or may be taken together with the nitrogen to which they are attached to form an azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl or thiomopholinyl ring;<br><br> INTELLECTUAL PROPERTY OFFICE OF N.Z.<br><br> m jul 2000<br><br> RECEIVED<br><br> -59-<br><br> ^36836<br><br> R21 is H2N(CHR22)(C=0)-;<br><br> R22 is the side chain of a natural D- or L-amino acid;<br><br> R23 is hydrogen, (C1-C6)acyl, (C1-C6)alkyl, (Cg-C^JaryKCrC^alkyl, (CVC^heteroaryKCr CB)alkyl or (C^-CsJalkylsulfonyl;<br><br> R24 wherever it occurs is independently hydrogen or (C,-C6)alkyl;<br><br> or R1 and R2, or R3 and R4, or R5 and R6 may be taken together to form a carbonyl; or R1 and R2, or R3 and R4, or R5 and R6, or R7 and R8 may be taken together to form a (C3-C6)cycloalkyl, oxacyclohexyl, thiocyclohexyl, indanyl or tetralinyl ring or a group of the<br><br> Q is (Cs-C10)aryi(C1-C8)alkoxy(C6-C10)aryl optionally substituted by fluoro, chloro, (Cn-C^aikyl, (C1-C,)alkoxy or perfluoro(C1-C3)alkyl;<br><br> with the proviso that when R1, R2, R3, R4, R5, R6, R7, R*, and R9 are all defined by hydrogen or (C1-Cs)alkyl, the broken line represents a double bond;<br><br> with the proviso that when R1, R2 and R9 are a substituent comprising a heteroatom, the heteroatom cannot be directly bonded to the 2- or 6- positions of the ring;<br><br> with the proviso that when y is 1 and W is NF?4 or oxygen, Z cannot be hydroxy;<br><br> with the proviso that when the broken line represents a double bond, R4 and R6 are not present;<br><br> with the proviso that when R3 and R5 are independently a substituent comprising a heteroatom when the broken line represents a double bond, the heteroatom cannot be directly bonded to positions X and Y.<br><br> 4. A compound according to claim 1, wherein R2, R3, R6, R7 and R9 are hydrogen.<br><br> 5. A compound according to claim 1, wherein at least one of R7-R9 is other than hydrogen.<br><br> formula<br><br> R23<br><br> 6.<br><br> R7-R9 is (CrC^alkyl.<br><br> A compound according to claim 1, wherein at least one of intellectual property office of N.Z.<br><br> - 5 DEC 2000<br><br> RECEIVED<br><br> j36836<br><br> -60-<br><br> 7. A compound according to claim 1, wherein in at least one of R7-R9 is methyl.<br><br> 8. A compound according to claim 1, wherein R7 and R8 are taken together to form a carbonyl and R9 is ((VCelalkyl.<br><br> 9. A compound according to claim 1, wherein R7 and R8 are each methyl.<br><br> 10. A compound according to claim 1, wherein R7 arid R8 are taken together to form a (C3-C6)cycloalkyl group.<br><br> 11. A corripound according to claim 1, wherein R1-R9 are hydrogen, hydroxy or (C,-C6)-alkyl and Q is benzyloxyphenyl.<br><br> 12. A compound according to claim 1, wherein said compound is selected from the group consisting of:<br><br> # (2f?,4f?)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidine-4-<br><br> carboxyiic acid;<br><br> (2R,4R)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyi]-2-hydroxycarbamoyl-piperidine-4-carboxyiic acid methyl ester;<br><br> (2R,4f?)-1-[3-(4-Fluorophenoxy)-propane-1-sulfonyQ-2-hydroxycarbamoyl-piperidine-4-carboxyiic add;<br><br> (2R,4/?)-1-[3-(4-Fluorophenoxy)-propane-1-sulfonyl]-2-hydroxycarbamoyl-piperidine-4-carboxyiic acid methyl ester;<br><br> (2ft,3SHH4-(4-Fluorobenzyloxy)-benzenesulfonyl]-2-hydroxycarbamoyl-piperidin-3-yl}-carbamic acid isopropyl ester;<br><br>
3-(S)-
4-{4'-Fluorobiphenyl-4-sulfonyl)-2,2-dimethyl-thiomorpholine-3-carboxylic acid hydroxyamide;<br><br> ^ 3-{S)-4-[4-{4-Fluorobenzyloxy)benzenesulfonyl]-2,2-dimethyl-thiomorpholine-3 -<br><br> carboxyiic acid hydroxyamide;<br><br> (2R,4S)-1-[4-(4-Fluorobenzyloxy)-benzenesulfonyl]-4-hydroxy-piperidine-2-carboxylic acid hydroxyamide; and<br><br> (2R,4R)-1-(4-Methoxybenzenesulfonyl)-4-(piperazine-1-carbonyl)-piperidine-2-carboxylic acid hydroxyamide hydrochloride.<br><br> 13. A pharmaceutical composition for (a) the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis,<br><br> and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (iTNO or (b) tho inhi intellectual prope<br><br> -inhibitio n of property office OF n.z.<br><br> - 5 DEC 2000<br><br> RECEIVED<br><br> 336836<br><br> matrix metalloproteinases or the production of tumor necrosis factor (TNF) in a mammal, including a human, comprising an amount of a compound of claim 1 effective in such treatment and a pharmaceuticaily acceptable carrier.<br><br> 14. A pharmaceutical composition as claimed in claim 13, wherein said composition further comprises a standard NSAID, analgesic or cytotoxic anticancer agent.<br><br> 15. The use of an effective amount of a compound of claim 1 in the manufacture of a medicament for the inhibition of (a) matrix metalloproteinases or (b) the production of tumor necrosis factor (TNF) in a mammal, including a human.<br><br> 16. The use of an effective amount of a compound of claim 1, in the manufacture of a medicament for treating a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of tumor necrosis factor (TNF) in a mammal, including a human.<br><br> 17. Use as claimed in claim 16, wherein the medicament further comprises a standard NSAID, analgesic or cytotoxic anticancer agent.<br><br> 18. Use as claimed in claim 17, wherein said medicament is formulated for simultaneous or sequential administration of the NSAID, analgesic or cytotoxic anticancer agent.<br><br> 19. A compound of formula (I) as claimed in claim 1 substantially as herein described or exemplified.<br><br> 20. A pharmaceutical composition as claimed in claim 13 substantially as herein described or exemplified.<br><br> 21. A use as claimed in claim 15 or 16 substantially as herein described or exemplified.<br><br> intellectual property office of n.z.<br><br> 2 1 dec 2000 received<br><br> END<br><br> </p> </div>
NZ336836A 1997-02-11 1998-01-16 Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments NZ336836A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3760097P 1997-02-11 1997-02-11
PCT/IB1998/000064 WO1998034918A1 (en) 1997-02-11 1998-01-16 Arylsulfonyl hydroxamic acid derivatives

Publications (1)

Publication Number Publication Date
NZ336836A true NZ336836A (en) 2001-02-23

Family

ID=21895216

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ336836A NZ336836A (en) 1997-02-11 1998-01-16 Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments

Country Status (37)

Country Link
US (1) US6599890B1 (en)
EP (1) EP0960098A1 (en)
JP (1) JP3710489B2 (en)
KR (1) KR20000070923A (en)
CN (1) CN1247531A (en)
AP (1) AP958A (en)
AR (1) AR011123A1 (en)
AU (1) AU722784B2 (en)
BG (1) BG63430B1 (en)
BR (1) BR9807678A (en)
CA (1) CA2280151C (en)
CO (1) CO4950619A1 (en)
DZ (1) DZ2416A1 (en)
EA (1) EA002546B1 (en)
GT (1) GT199800026A (en)
HN (1) HN1998000020A (en)
HR (1) HRP980070B1 (en)
HU (1) HUP0000657A3 (en)
ID (1) ID22809A (en)
IL (1) IL131123A0 (en)
IS (1) IS5130A (en)
MA (1) MA24469A1 (en)
NO (1) NO993836L (en)
NZ (1) NZ336836A (en)
OA (1) OA11142A (en)
PA (1) PA8446101A1 (en)
PE (1) PE58699A1 (en)
PL (1) PL334997A1 (en)
SA (1) SA98180856A (en)
SK (1) SK101399A3 (en)
TN (1) TNSN98025A1 (en)
TR (1) TR199901926T2 (en)
TW (1) TW502020B (en)
UY (1) UY24880A1 (en)
WO (1) WO1998034918A1 (en)
YU (1) YU37499A (en)
ZA (1) ZA981061B (en)

Families Citing this family (278)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002546B1 (en) * 1997-02-11 2002-06-27 Пфайзер Инк. Arylsulfonyl hydroxamic acid derivatives
AU3982599A (en) 1998-05-14 1999-11-29 Du Pont Pharmaceuticals Company Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
UA59453C2 (en) * 1998-08-12 2003-09-15 Пфайзер Продактс Інк. HYDROXYPIPECOLATE HYDROXAMIC ACID DERIVATIVES AS matrix metalloproteinase inhibitors
ES2242402T3 (en) * 1998-08-12 2005-11-01 Pfizer Products Inc. TACE INHIBITORS.
AU6228499A (en) * 1998-10-22 2000-05-08 Akzo Nobel N.V. Tetrahydropyridopyridine derivatives and intermediates for producing the same
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
CN1178915C (en) 1999-01-27 2004-12-08 惠氏控股有限公司 Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (MMP) inhibitors/TNF-alpha converting enzyme (TACE) inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
EP1081137A1 (en) 1999-08-12 2001-03-07 Pfizer Products Inc. Selective inhibitors of aggrecanase in osteoarthritis treatment
UA74803C2 (en) 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
US6462063B1 (en) 2000-02-04 2002-10-08 Fibrogen, Inc. C-proteinase inhibitors
US6458822B2 (en) 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
EP1138680A1 (en) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
GB0011409D0 (en) * 2000-05-11 2000-06-28 Smithkline Beecham Plc Novel compounds
JP2001322977A (en) * 2000-05-12 2001-11-20 Kotobuki Seiyaku Kk Pipecolic acid derivative and method for producing the same and pharmaceutical composition containing the same
NZ569856A (en) 2001-01-05 2010-03-26 Pfizer Antibodies to insulin-like growth factor 1 receptor
MXPA01013326A (en) * 2001-02-14 2002-08-26 Warner Lambert Co Biphenyl sulfonamides useful as matrix metalloproteinase inhibitors.
MXPA01013171A (en) 2001-02-14 2004-05-21 Warner Lambert Co Tricyclic biphenyl sulfonamide matrix metalloproteinase inhibitors.
MXPA01013172A (en) * 2001-02-14 2002-08-21 Warner Lambert Co Sulfonamide matrix metalloproteinase inhibitors.
AU2002345792A1 (en) 2001-06-21 2003-01-08 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
AUPR726201A0 (en) * 2001-08-24 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. New use of a cyclic compound
BR0213736A (en) 2001-11-01 2004-10-19 Wyeth Corp allenic aryl sulfonamide hydroxamic acids as matrix metalloproteinase and tace inhibitors
AR039067A1 (en) 2001-11-09 2005-02-09 Pfizer Prod Inc ANTIBODIES FOR CD40
WO2003074529A2 (en) 2002-03-01 2003-09-12 Pfizer Inc. iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
DK3000810T3 (en) 2002-03-13 2017-10-16 Array Biopharma Inc N3-ALKYLED BENZIMIDAZOLE DERIVATIVE AS MEK INHIBITOR
ES2425013T3 (en) 2002-06-12 2013-10-10 Symphony Evolution, Inc. Human ADAM-10 inhibitors
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
EP1585743B1 (en) 2002-12-19 2007-05-23 Pfizer Inc. 2-(1h-indazol-6-ylamino)- benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases
AU2003304456A1 (en) 2002-12-23 2005-03-16 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors
WO2004076412A2 (en) 2003-02-26 2004-09-10 Sugen, Inc. Aminoheteroaryl compounds as protein kinase inhibitors
ATE412655T1 (en) 2003-08-29 2008-11-15 Pfizer THIENOPYRIDINPHENYLACETAMIDE AND DERIVATIVES THEREOF SUITABLE AS NEW ANTIANGIOGENIC AGENTS
US7144907B2 (en) 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AR045563A1 (en) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
CN1905873A (en) 2003-11-19 2007-01-31 阵列生物制药公司 Bicyclic inhibitors of MEK and methods of use thereof
GT200500139A (en) * 2004-06-08 2005-07-25 METHOD FOR THE PREPARATION OF HYDROXAMIC ACIDS
EA013678B1 (en) 2004-08-26 2010-06-30 Пфайзер Инк. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
US7429667B2 (en) 2005-01-20 2008-09-30 Ardea Biosciences, Inc. Phenylamino isothiazole carboxamidines as MEK inhibitors
CA2608201C (en) 2005-05-18 2013-12-31 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
ES2374450T3 (en) 2005-09-20 2012-02-16 OSI Pharmaceuticals, LLC ANTI-BANGEOUS RESPONSE BIOLOGICAL MARKERS FOR KINNER INHIBITORS OF THE GROWTH FACTOR RECEIVER 1 SIMILAR TO INSULIN.
TWI405756B (en) 2005-12-21 2013-08-21 Array Biopharma Inc Novel hydrogen sulfate salt
US7842836B2 (en) 2006-04-11 2010-11-30 Ardea Biosciences N-aryl-N'alkyl sulfamides as MEK inhibitors
CN101454004B (en) 2006-04-18 2013-12-04 阿迪亚生命科学公司 Pyridone sulfonamides and pyridone sulfamides as mek inhibitors
US20100029615A1 (en) 2006-12-15 2010-02-04 Michael John Munchhof Benzimidazole derivatives
EA200900959A1 (en) 2007-01-19 2010-02-26 Арди Байосайенсиз, Инк. MEK INHIBITORS
CA2684447C (en) 2007-04-18 2012-01-24 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth
US8530463B2 (en) 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
CA2924418A1 (en) 2007-07-30 2009-02-05 Jean-Michel Vernier Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same
MX2010006800A (en) 2007-12-19 2010-10-05 Genentech Inc 5-anilinoimidazopyridines and methods of use.
KR101660050B1 (en) 2008-01-04 2016-09-26 인텔리카인, 엘엘씨 Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2252293B1 (en) 2008-03-14 2018-06-27 Intellikine, LLC Kinase inhibitors and methods of use
ES2586032T3 (en) 2008-03-28 2016-10-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
NZ590258A (en) 2008-07-08 2013-10-25 Intellikine Llc Kinase inhibitors and methods of use
US8476410B2 (en) 2008-10-16 2013-07-02 University of Pittsburgh—of the Commonwealth System of Higher Education Fully human antibodies to high molecular weight-melanoma associated antigen and uses thereof
US8476282B2 (en) 2008-11-03 2013-07-02 Intellikine Llc Benzoxazole kinase inhibitors and methods of use
NZ594177A (en) 2009-02-05 2014-02-28 Immunogen Inc Novel benzodiazepine derivatives
WO2010090764A1 (en) 2009-02-09 2010-08-12 Supergen, Inc. Pyrrolopyrimidinyl axl kinase inhibitors
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099137A2 (en) 2009-02-26 2010-09-02 Osi Pharmaceuticals, Inc. In situ methods for monitoring the emt status of tumor cells in vivo
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
JP2012519282A (en) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー Methods for identifying mesenchymal tumor cells or agents that inhibit their production
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
JP2012519281A (en) 2009-02-27 2012-08-23 オーエスアイ・ファーマシューティカルズ,エルエルシー Methods for identifying mesenchymal tumor cells or agents that inhibit their production
US8673919B2 (en) 2009-03-27 2014-03-18 Ardea Biosciences, Inc. Dihydropyridin sulfonamides and dihydropyridin sulfamides as MEK inhibitors
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
JP2013500991A (en) 2009-07-31 2013-01-10 オーエスアイ・ファーマシューティカルズ,エルエルシー mTOR inhibitor and angiogenesis inhibitor combination therapy
IN2012DN01961A (en) 2009-08-17 2015-08-21 Intellikine Llc
CA2772194A1 (en) 2009-09-01 2011-03-10 Pfizer Inc. Benzimidazole derivatives
AU2010306830C1 (en) 2009-10-13 2015-05-28 Allomek Therapeutics Llc Novel mek inhibitors, useful in the treatment of diseases
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
KR101821768B1 (en) 2009-11-05 2018-01-24 리젠 파마슈티컬스 소시에떼 아노님 Novel benzopyran kinase modulators
CA2789629A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc. Cd20 antibodies and uses thereof
DK2534153T3 (en) 2010-02-12 2017-01-09 Pfizer Salts and polymorphs of 8-fluoro-2- {4 - [(methylamino} methyl] phenyl} -1,3,4,5-tetrahydro-6H-azepino [5,4,3-cd] indole-6-one
WO2011109584A2 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
AU2011223643A1 (en) 2010-03-03 2012-06-28 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CN107674073B (en) 2010-05-17 2021-09-10 印蔻真治疗公司 3, 5-disubstituted-3H-imidazo [4,5-B ] pyridine compounds as modulators of protein kinases
CN103002738A (en) 2010-05-21 2013-03-27 英特利凯恩有限责任公司 Chemical compounds, compositions and methods for kinase modulation
AU2011268356B2 (en) 2010-06-16 2013-09-19 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Antibodies to endoplasmin and their use
EP2630134B9 (en) 2010-10-20 2018-04-18 Pfizer Inc Pyridine-2- derivatives as smoothened receptor modulators
EP2637669A4 (en) 2010-11-10 2014-04-02 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
MX347708B (en) 2011-01-10 2017-05-09 Infinity Pharmaceuticals Inc Processes for preparing isoquinolinones and solid forms of isoquinolinones.
WO2012106556A2 (en) 2011-02-02 2012-08-09 Amgen Inc. Methods and compositons relating to inhibition of igf-1r
AU2012231640B2 (en) 2011-02-15 2015-07-09 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
US20120214830A1 (en) 2011-02-22 2012-08-23 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
WO2012116237A2 (en) 2011-02-23 2012-08-30 Intellikine, Llc Heterocyclic compounds and uses thereof
WO2012142164A1 (en) 2011-04-12 2012-10-18 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies that bind insulin-like growth factor (igf) i and ii
EP3536708A1 (en) 2011-04-19 2019-09-11 Pfizer Inc Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
US9775841B2 (en) 2011-05-04 2017-10-03 Rhizen Pharmaceuticals Sa Compounds as modulators of protein kinases
CN107737100A (en) 2011-06-14 2018-02-27 哈尔生物药投资有限责任公司 The administration of Benzodiazepine composition
MX2014000648A (en) 2011-07-19 2014-09-25 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof.
JP6027610B2 (en) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ, インコーポレイテッド Heterocyclic compounds and uses thereof
PT3409278T (en) 2011-07-21 2020-12-18 Sumitomo Dainippon Pharma Oncology Inc Heterocyclic protein kinase inhibitors
SG11201400310WA (en) 2011-08-29 2014-06-27 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
PE20141228A1 (en) 2011-09-22 2014-10-01 Pfizer DERIVATIVES OF PYRROLOPYRIMIDINE AND PURINE
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
JP2014528963A (en) * 2011-10-04 2014-10-30 インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル)Inserm(Institut National Dela Sante Etde La Recherche Medicale) Novel apoptosis-inducing compound
WO2013050725A1 (en) 2011-10-04 2013-04-11 King's College London Ige anti -hmw-maa antibody
RU2014114015A (en) 2011-11-08 2015-12-20 Пфайзер Инк. METHODS FOR TREATING INFLAMMATORY DISORDERS USING ANTIBODIES AGAINST M-CSF
WO2013126617A1 (en) 2012-02-22 2013-08-29 The Regents Of The University Of Colorado, A Body Corporate Bouvardin derivatives and therapeutic uses thereof
US9452215B2 (en) 2012-02-22 2016-09-27 The Regents Of The University Of Colorado Bourvadin derivatives and therapeutic uses thereof
CA2865719C (en) 2012-03-30 2020-09-22 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3505534A1 (en) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
BR112015004022B1 (en) 2012-08-31 2023-04-25 Sutro Biopharma, Inc MODIFIED AMINO ACIDS COMPRISING AN AZID GROUP
DK2909181T3 (en) 2012-10-16 2017-11-20 Tolero Pharmaceuticals Inc PKM2 modulators and methods for their use
JP6584952B2 (en) 2012-11-01 2019-10-02 インフィニティー ファーマシューティカルズ, インコーポレイテッド Treatment of cancer using PI3 kinase isoform modulator
EP3566750A3 (en) 2013-02-28 2020-04-08 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP2961435B1 (en) 2013-02-28 2019-05-01 ImmunoGen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
MX2015012062A (en) 2013-03-14 2016-05-05 Tolero Pharmaceuticals Inc Jak2 and alk2 inhibitors and methods for their use.
EP2970121B1 (en) 2013-03-15 2017-12-13 Araxes Pharma LLC Covalent inhibitors of kras g12c
NZ629037A (en) 2013-03-15 2017-04-28 Infinity Pharmaceuticals Inc Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc Combination of kinase inhibitors and uses thereof
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
WO2014143659A1 (en) 2013-03-15 2014-09-18 Araxes Pharma Llc Irreversible covalent inhibitors of the gtpase k-ras g12c
MX2015016277A (en) 2013-05-30 2016-08-11 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators.
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
ES2658039T3 (en) 2013-07-10 2018-03-08 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods for their preparation and methods of use
JP6427197B2 (en) 2013-10-03 2018-11-21 クラ オンコロジー, インコーポレイテッド Inhibitors of ERK and methods of use
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX2021012208A (en) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof.
EP3636639A1 (en) 2013-10-10 2020-04-15 Araxes Pharma LLC Inhibitors of kras g12c
JO3805B1 (en) 2013-10-10 2021-01-31 Araxes Pharma Llc Inhibitors of kras g12c
WO2015054658A1 (en) 2013-10-11 2015-04-16 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
UA115388C2 (en) 2013-11-21 2017-10-25 Пфайзер Інк. 2,6-substituted purine derivatives and their use in the treatment of proliferative disorders
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
TN2016000459A1 (en) 2014-04-30 2018-04-04 Pfizer Cycloalkyl-linked diheterocycle derivatives.
HUE042390T2 (en) 2014-06-19 2019-06-28 Ariad Pharma Inc Heteroaryl compounds for kinase inhibition
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
JP6811706B2 (en) 2014-07-31 2021-01-13 ザ ホンコン ユニヴァーシティ オブ サイエンス アンド テクノロジー Human monoclonal antibodies against EPHA4 and their use
JO3556B1 (en) 2014-09-18 2020-07-05 Araxes Pharma Llc Combination therapies for treatment of cancer
JP2017528498A (en) 2014-09-25 2017-09-28 アラクセス ファーマ エルエルシー Inhibitors of KRAS G12C mutant protein
WO2016049568A1 (en) 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
EP3233829B1 (en) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors
JP2018513853A (en) 2015-04-10 2018-05-31 アラクセス ファーマ エルエルシー Substituted quinazoline compounds and methods of use thereof
CA2982360A1 (en) 2015-04-15 2016-10-20 Liansheng Li Fused-tricyclic inhibitors of kras and methods of use thereof
EP3611506B1 (en) 2015-04-20 2021-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Predicting response to alvocidib by mitochondrial profiling
EP3288957A4 (en) 2015-05-01 2019-01-23 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
PL3298021T3 (en) 2015-05-18 2019-11-29 Tolero Pharmaceuticals Inc Alvocidib prodrugs having increased bioavailability
AR104020A1 (en) 2015-06-04 2017-06-21 Kura Oncology Inc METHODS AND COMPOSITIONS TO INHIBIT THE INTERACTION OF MENINA WITH MILL PROTEINS
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10568887B2 (en) 2015-08-03 2020-02-25 Tolero Pharmaceuticals, Inc. Combination therapies for treatment of cancer
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10647703B2 (en) 2015-09-28 2020-05-12 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058805A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3364977A4 (en) 2015-10-19 2019-09-04 Araxes Pharma LLC Method for screening inhibitors of ras
AU2016355433C1 (en) 2015-11-16 2021-12-16 Araxes Pharma Llc 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
CN108601752A (en) 2015-12-03 2018-09-28 安吉奥斯医药品有限公司 MAT2A inhibitor for treating MTAP deletion form cancers
US9988357B2 (en) 2015-12-09 2018-06-05 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
KR20180104106A (en) 2016-01-27 2018-09-19 서트로 바이오파마, 인크. an anti-CD74 antibody conjugate, a composition comprising an anti-CD74 antibody conjugate, and an anti-CD74 antibody conjugate
MX2018011105A (en) 2016-03-16 2018-11-22 Kura Oncology Inc Substituted inhibitors of menin-mll and methods of use.
EP3429585B1 (en) 2016-03-16 2021-11-24 Kura Oncology, Inc. Bridged bicyclic inhibitors of menin-mll and methods of use
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
AU2017263574B2 (en) 2016-05-12 2022-11-17 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
WO2017201302A1 (en) 2016-05-18 2017-11-23 The University Of Chicago Btk mutation and ibrutinib resistance
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
WO2018045379A1 (en) 2016-09-02 2018-03-08 Dana-Farber Cancer Institute, Inc. Composition and methods of treating b cell disorders
WO2018064510A1 (en) 2016-09-29 2018-04-05 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
US11279694B2 (en) 2016-11-18 2022-03-22 Sumitomo Dainippon Pharma Oncology, Inc. Alvocidib prodrugs and their use as protein kinase inhibitors
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
EP3362471B1 (en) 2016-12-19 2021-11-17 Sumitomo Dainippon Pharma Oncology, Inc. Profiling peptides and methods for sensitivity profiling
RS62456B1 (en) 2016-12-22 2021-11-30 Amgen Inc Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as kras g12c inhibitors for treating lung, pancreatic or colorectal cancer
JP2020505395A (en) 2017-01-26 2020-02-20 アラクセス ファーマ エルエルシー Fused N-heterocyclic compounds and methods of use
US11059819B2 (en) 2017-01-26 2021-07-13 Janssen Biotech, Inc. Fused hetero-hetero bicyclic compounds and methods of use thereof
WO2018140512A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018137705A1 (en) 2017-01-26 2018-08-02 Zai Lab (Shanghai) Co., Ltd. Cd47 antigen binding unit and uses thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
US11279689B2 (en) 2017-01-26 2022-03-22 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer
WO2018175746A1 (en) 2017-03-24 2018-09-27 Kura Oncology, Inc. Methods for treating hematological malignancies and ewing's sarcoma
JOP20190272A1 (en) 2017-05-22 2019-11-21 Amgen Inc Kras g12c inhibitors and methods of using the same
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
EP3630747A1 (en) 2017-05-25 2020-04-08 Araxes Pharma LLC Quinazoline derivatives as modulators of mutant kras, hras or nras
CN110869357A (en) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Compounds and methods of use thereof for treating cancer
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
EP3679040B1 (en) 2017-09-08 2022-08-03 Amgen Inc. Inhibitors of kras g12c and methods of using the same
JP7196160B2 (en) 2017-09-12 2022-12-26 スミトモ ファーマ オンコロジー, インコーポレイテッド Treatment Regimens for Cancers Insensitive to BCL-2 Inhibitors Using the MCL-1 Inhibitor Albocidib
KR20200051802A (en) 2017-09-18 2020-05-13 서트로 바이오파마, 인크. Anti-folate receptor alpha antibody conjugates and uses thereof
US11649251B2 (en) 2017-09-20 2023-05-16 Kura Oncology, Inc. Substituted inhibitors of menin-MLL and methods of use
US20200237766A1 (en) 2017-10-13 2020-07-30 Tolero Pharmaceuticals, Inc. Pkm2 activators in combination with reactive oxygen species for treatment of cancer
CA3082077A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l degraders and methods of treatment therewith
CA3084809A1 (en) 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
BR112020020246A8 (en) 2018-04-05 2022-10-18 Sumitomo Dainippon Pharma Oncology Inc AXL KINASE INHIBITORS AND THEIR USE
EP3788038B1 (en) 2018-05-04 2023-10-11 Amgen Inc. Kras g12c inhibitors and methods of using the same
EP3788053A1 (en) 2018-05-04 2021-03-10 Amgen Inc. Kras g12c inhibitors and methods of using the same
CA3099045A1 (en) 2018-05-10 2019-11-14 Amgen Inc. Kras g12c inhibitors for the treatment of cancer
MX2020012731A (en) 2018-06-01 2021-02-22 Amgen Inc Kras g12c inhibitors and methods of using the same.
CN112533581A (en) 2018-06-07 2021-03-19 密歇根大学董事会 PRC1 inhibitors and methods of treatment therewith
JP7357644B2 (en) 2018-06-11 2023-10-06 アムジエン・インコーポレーテツド KRAS G12C inhibitors for treating cancer
US11285156B2 (en) 2018-06-12 2022-03-29 Amgen Inc. Substituted piperazines as KRAS G12C inhibitors
JP2021530554A (en) 2018-07-26 2021-11-11 スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド Methods and ACVR1 Inhibitors for Treatment of Diseases with Abnormal ACVR1 Expression
CA3107168A1 (en) 2018-08-01 2020-02-06 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
US20220047716A1 (en) 2018-09-17 2022-02-17 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
MX2021004624A (en) 2018-10-24 2021-05-27 Araxes Pharma Llc 2-(2-acryloyl-2,6-diazaspiro[3.4]octan-6-yl)-6-(1h-indazol-4-yl) -benzonitrile derivatives and related compounds as inhibitors of g12c mutant kras protein for inhibiting tumor metastasis.
JP2020090482A (en) 2018-11-16 2020-06-11 アムジエン・インコーポレーテツド Improved synthesis of key intermediate of kras g12c inhibitor compound
WO2020106640A1 (en) 2018-11-19 2020-05-28 Amgen Inc. Kras g12c inhibitors and methods of using the same
JP7377679B2 (en) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer
CA3120383A1 (en) 2018-11-29 2020-06-04 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
AU2019391097A1 (en) 2018-12-04 2021-05-20 Sumitomo Pharma Oncology, Inc. CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
JP2022514268A (en) 2018-12-20 2022-02-10 アムジエン・インコーポレーテツド KIF18A inhibitor
MX2021007157A (en) 2018-12-20 2021-08-16 Amgen Inc Heteroaryl amides useful as kif18a inhibitors.
PE20211475A1 (en) 2018-12-20 2021-08-05 Amgen Inc KIF18A INHIBITORS
MX2021007158A (en) 2018-12-20 2021-08-16 Amgen Inc Heteroaryl amides useful as kif18a inhibitors.
US11471456B2 (en) 2019-02-12 2022-10-18 Sumitomo Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
MX2021010319A (en) 2019-03-01 2021-12-10 Revolution Medicines Inc Bicyclic heteroaryl compounds and uses thereof.
MX2021010323A (en) 2019-03-01 2021-12-10 Revolution Medicines Inc Bicyclic heterocyclyl compounds and uses thereof.
JP2022525149A (en) 2019-03-20 2022-05-11 スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド Treatment of Acute Myeloid Leukemia (AML) with Venetoclax Failure
JP2022519923A (en) 2019-03-22 2022-03-25 スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド Compositions comprising a PKM2 modulator and methods of treatment using it
WO2020227105A1 (en) 2019-05-03 2020-11-12 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
EP3972973A1 (en) 2019-05-21 2022-03-30 Amgen Inc. Solid state forms
CN114302878A (en) 2019-07-03 2022-04-08 大日本住友制药肿瘤公司 Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof
MX2022001296A (en) 2019-08-02 2022-02-22 Amgen Inc Kif18a inhibitors.
AU2020325115A1 (en) 2019-08-02 2022-03-17 Amgen Inc. Pyridine derivatives as KIF18A inhibitors
US20220289724A1 (en) 2019-08-02 2022-09-15 Amgen Inc. Kif18a inhibitors
AU2020324963A1 (en) 2019-08-02 2022-02-24 Amgen Inc. KIF18A inhibitors
TW202126636A (en) 2019-09-30 2021-07-16 美商阿吉歐斯製藥公司 Piperidine compounds as menin inhibitors
AU2020369569A1 (en) 2019-10-24 2022-04-14 Amgen Inc. Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
WO2021086833A1 (en) 2019-10-28 2021-05-06 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
EP4051266A1 (en) 2019-10-31 2022-09-07 Taiho Pharmaceutical Co., Ltd. 4-aminobut-2-enamide derivatives and salts thereof
WO2021091982A1 (en) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Ras inhibitors
US11739074B2 (en) 2019-11-04 2023-08-29 Revolution Medicines, Inc. Ras inhibitors
CR20220243A (en) 2019-11-04 2022-08-04 Revolution Medicines Inc Ras inhibitors
CR20220200A (en) 2019-11-08 2022-07-28 Revolution Medicines Inc Bicyclic heteroaryl compounds and uses thereof
US20230192682A1 (en) 2019-11-14 2023-06-22 Amgen Inc. Improved synthesis of kras g12c inhibitor compound
TW202132296A (en) 2019-11-14 2021-09-01 美商安進公司 Improved synthesis of kras g12c inhibitor compound
WO2021108683A1 (en) 2019-11-27 2021-06-03 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
AU2021206217A1 (en) 2020-01-07 2022-09-01 Revolution Medicines, Inc. SHP2 inhibitor dosing and methods of treating cancer
WO2021155006A1 (en) 2020-01-31 2021-08-05 Les Laboratoires Servier Sas Inhibitors of cyclin-dependent kinases and uses thereof
WO2021178597A1 (en) 2020-03-03 2021-09-10 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
WO2021207310A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
WO2021204159A1 (en) 2020-04-08 2021-10-14 Agios Pharmaceuticals, Inc. Menin inhibitors and methods of use for treating cancer
WO2021215545A1 (en) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Anticancer combination therapy with n-(1-acryloyl-azetidin-3-yl)-2-((1h-indazol-3-yl)amino)methyl)-1h-imidazole-5-carboxamide inhibitor of kras-g12c
US20230174518A1 (en) 2020-04-24 2023-06-08 Taiho Pharmaceutical Co., Ltd. Kras g12d protein inhibitors
MX2022016355A (en) 2020-06-18 2023-04-03 Revolution Medicines Inc Methods for delaying, preventing, and treating acquired resistance to ras inhibitors.
US11858925B2 (en) 2020-07-10 2024-01-02 The Regents Of The University Of Michigan GAS41 inhibitors and methods of use thereof
AU2021308045A1 (en) 2020-07-15 2023-02-23 Taiho Pharmaceutical Co., Ltd. Pyrimidine compound-containing combination to be used in tumor treatment
MX2023002248A (en) 2020-09-03 2023-05-16 Revolution Medicines Inc Use of sos1 inhibitors to treat malignancies with shp2 mutations.
JP2023541916A (en) 2020-09-15 2023-10-04 レボリューション メディシンズ インコーポレイテッド Indole derivatives as RAS inhibitors in the treatment of cancer
TW202237119A (en) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk-5 inhibitors and uses thereof
AU2021409816A1 (en) 2020-12-22 2023-07-06 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
EP4323356A1 (en) 2021-04-13 2024-02-21 Nuvalent, Inc. Amino-substituted heterocycles for treating cancers with egfr mutations
BR112023022819A2 (en) 2021-05-05 2024-01-16 Revolution Medicines Inc COMPOUNDS, PHARMACEUTICAL COMPOSITION, CONJUGATES AND METHODS FOR TREATING CANCER IN A SUBJECT, FOR TREATING A DISORDER AND FOR INHIBITING A RAS PROTEIN IN A CELL
KR20240017811A (en) 2021-05-05 2024-02-08 레볼루션 메디슨즈, 인크. RAS inhibitors for the treatment of cancer
WO2022235866A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
WO2022250170A1 (en) 2021-05-28 2022-12-01 Taiho Pharmaceutical Co., Ltd. Small molecule inhibitors of kras mutated proteins
AR127308A1 (en) 2021-10-08 2024-01-10 Revolution Medicines Inc RAS INHIBITORS
WO2023056589A1 (en) 2021-10-08 2023-04-13 Servier Pharmaceuticals Llc Menin inhibitors and methods of use for treating cancer
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023211812A1 (en) 2022-04-25 2023-11-02 Nested Therapeutics, Inc. Heterocyclic derivatives as mitogen-activated protein kinase (mek) inhibitors
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2024006542A1 (en) 2022-06-30 2024-01-04 Sutro Biopharma, Inc. Anti-ror1 antibodies and antibody conjugates, compositions comprising anti-ror1 antibodies or antibody conjugates, and methods of making and using anti-ror1 antibodies and antibody conjugates
WO2024010925A2 (en) 2022-07-08 2024-01-11 Nested Therapeutics, Inc. Mitogen-activated protein kinase (mek) inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
ES2153031T4 (en) * 1995-04-20 2001-05-16 Pfizer ARILSULFONIL HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF MMP AND TNF.
US5753653A (en) 1995-12-08 1998-05-19 Agouron Pharmaceuticals, Inc. Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
PL331802A1 (en) 1996-08-28 1999-08-02 Procter & Gamble Substituted cyclic amines as metaloprotease inhibitors
HUP0000591A3 (en) 1996-08-28 2001-07-30 Procter & Gamble Piperazine, morpholine and thiomorpholine derivatives as metalloprotease inhibitors and use of them for producing pharmaceutical compositions
EA002546B1 (en) * 1997-02-11 2002-06-27 Пфайзер Инк. Arylsulfonyl hydroxamic acid derivatives
JPH11199512A (en) * 1997-10-24 1999-07-27 Pfizer Prod Inc Use of mmp-13 selective inhibitor for the treatment of arthrosis deformans and other mmp-mediated disease

Also Published As

Publication number Publication date
WO1998034918A1 (en) 1998-08-13
EA002546B1 (en) 2002-06-27
BG103641A (en) 2000-02-29
HUP0000657A3 (en) 2000-10-30
SA98180856A (en) 2005-12-03
HUP0000657A2 (en) 2000-09-28
KR20000070923A (en) 2000-11-25
YU37499A (en) 2002-09-19
HRP980070A2 (en) 1998-12-31
JP2000510162A (en) 2000-08-08
OA11142A (en) 2003-04-25
HN1998000020A (en) 1999-01-08
EA199900641A1 (en) 2000-04-24
HRP980070B1 (en) 2002-10-31
NO993836L (en) 1999-10-08
IS5130A (en) 1999-07-23
ID22809A (en) 1999-12-09
EP0960098A1 (en) 1999-12-01
IL131123A0 (en) 2001-01-28
AU5336698A (en) 1998-08-26
AR011123A1 (en) 2000-08-02
US6599890B1 (en) 2003-07-29
BR9807678A (en) 2000-02-15
ZA981061B (en) 1999-08-10
NO993836D0 (en) 1999-08-10
PL334997A1 (en) 2000-03-27
JP3710489B2 (en) 2005-10-26
MA24469A1 (en) 1998-10-01
AP958A (en) 2001-04-17
CO4950619A1 (en) 2000-09-01
TR199901926T2 (en) 1999-12-21
DZ2416A1 (en) 2003-01-04
CA2280151A1 (en) 1998-08-13
GT199800026A (en) 1999-07-27
PA8446101A1 (en) 2000-05-24
UY24880A1 (en) 2000-09-29
TNSN98025A1 (en) 2005-03-15
AU722784B2 (en) 2000-08-10
CN1247531A (en) 2000-03-15
BG63430B1 (en) 2002-01-31
CA2280151C (en) 2005-12-13
SK101399A3 (en) 2001-09-11
TW502020B (en) 2002-09-11
PE58699A1 (en) 1999-06-21

Similar Documents

Publication Publication Date Title
NZ336836A (en) Arylsulfonyl hydroxamic acid derivatives suitable for a broad range of medicinal treatments
CA2218503C (en) Arylsulfonyl hydroxamic acid derivatives
AP733A (en) Arylsulfonylamino hydroxamic acid derivatives.
KR100317146B1 (en) Arylsulfonylamino Hydroxamic Acid Derivatives
KR20080109915A (en) Organic compounds
EP0895988B1 (en) Arylsulfonylamino hydroxamic acid derivatives
US6509337B1 (en) Arylsulfonyl Hydroxamic Acid derivatives as MMP and TNF inhibitors
MXPA99007385A (en) Arylsulfonyl hydroxamic acid derivatives
KR100194258B1 (en) Arylsulfonyl Hydroxamic Acid Derivatives
CZ20012711A3 (en) Hydroxamic acid derivatives containing alkynyl group, their preparation and their use as inhibitors of intercellular material metalloproteinases (MMP) and inhibitors of TNF-alpha (TACE) converting enzyme
MXPA99001808A (en) Arylsulfonylamino hydroxamic acid derivatives

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)